Oncology Books

2618 products


  • Gynaecological Cancer Care

    Ausmed Publications Gynaecological Cancer Care

    1 in stock

    Book SynopsisGynaecological cancers represent the second most common group of cancers and the most common cause of cancer death in woman, but the needs of women with gynaecological cancer are frequently unrecognised and often neglected. A diagnosis of gynaecological cancer can threaten a woman's body image, fertility, sexuality, femininity, relationships, and various roles in life. Nurses and other health professionals who care for women with gynaecological cancer require a resource that covers a range of issues in depth and breadth if they are to provide comprehensive care. This book offers a rich resource of material - presented in a stimulating style. It provides expert, practical, person-centred, evidence-based advice for nurses and other health professionals who care for women with gynaecological cancer.

    1 in stock

    £25.38

  • Closing the Cancer Divide

    Harvard Global Equity Initiative Closing the Cancer Divide

    2 in stock

    Book Synopsis

    2 in stock

    £18.86

  • Evidence-Based Networks Ltd Problem Solving in Acute Oncology

    15 in stock

    Book SynopsisA team of experts in oncology and cancer care propose a template for improved services that can be used by any professional involved in the planning and delivery of acute oncology care around the world.Table of ContentsTransformation of Acute Oncology: Past, present and future; Nursing Developments in Acute Oncology; Carcinoma of Unknown Primary; The Oncology Patient on The Acute Medical Unit (AMU); Which patient should be admitted to critical care; Acute Oncology: Examples by Country; Cancer Emergencies in the Community. Cases: Complications of Systemic Therapy - Febrile Neutropenia, Tumour Lysis Syndrome, Antiangiogenic Therapy, Cardiac Toxicity, Liver Problems, Acute Kidney Injury, Anti-Cancer Treatment and the Kidney, Metabolic Complications, Diabetes, Cutaneous Manifestations of Chemotherapy. Complications of Systemic Therapy - Acute Diarrhoea and Mucositis, Peripheral Neurotoxicity, Central Neurotoxicity, Chemotherapy-Induced Lung Toxicity, Immunotherapy-Related GI Side Effects, Complex Treatment Side Effects for Metastatic Lung Cancer on Chemotherapy and an Immune Checkpoint Inhibitor, Rare Immune-Related Adverse Events Associated with Checkpoint Inhibitors, Complications of CAR-T Cell Therapy. Complications of Radiotherapy - Radiation Pneumonitis, Radiation-Induced Head and Neck Mucositis, Management of Radiotherapy-Related Acute Skin Reactions, Toxicity Related to Pelvic Radiotherapy, Central Nervous System Toxicity of Radiotherapy. Complications of Cancer - Metastatic Spinal Cord Compression, Superior Vena Cava Obstruction, Brain Metastases, Paraneoplastic Syndromes, Venous Thromboembolism, Malignant Renal Obstruction, Management of Malignant Ascites in the Acute Oncology Setting, Malignant Pleural Effusion, Metabolic Complications of Malignancy: Hypercalcaemia, Metabolic Complications of Malignancy: Hyponatraemia, Bowel Obstruction in Acute Oncology, Pericardial Effusion, Hyperviscosity Syndrome, Hyperleucocytosis and Leucostasis. Acute Palliative Care and Pain Control - A Case of a Patient with Metastatic Small Cell Lung Cancer with Chest Wall Pain, Neuropathic Cancer Pain.

    15 in stock

    £39.99

  • Springer Us Cancer Stem Cells

    Out of stock

    Book SynopsisCancer Stem Cells: Current Challenges and Future Perspectives.- Immunohistochemistry for Cancer Stem Cells Detection: Principles and Methods.- Isolating Cancer Stem Cells from Solid Tumors.- Surface Markers for the Identification of Cancer Stem Cells.- CD44-Based Detection of CSCs: CD44 Immunodetection by Flow Cytometry.- ALDH Activity Assay: A Method for Cancer Stem Cell (CSC) Identification and Isolation.- In Vitro Tumorigenic Assay: A Tumor Sphere Assay for Cancer Stem Cells.- Multicellular Tumoroids for Investigating Cancer Stem-Like Cells in the Heterogeneous Tumor Microenvironment.- Generation, Expansion, and Biobanking of Gastrointestinal Patient-Derived Organoids from Tumor and Normal Tissues.- Prostate Cancer Organoids for Tumor Modeling and Drug Screening.- Mimicking the Tumor Niche: Methods for Isolation, Culture, and Characterization of Cancer Stem Cells and Multicellular Spheroids.- Detection of Cancer Stem Cells in Normal and Dysplastic/Leukemic Human Blood.- Methods to Study the Role of Mechanical Signals in the Induction of Cancer Stem Cells.- Co-Delivery Polymeric Poly(Lactic-co-Glycolic Acid) (PLGA) Nanoparticles to Target Cancer Stem-Like Cells.- Isolating Circulating Cancer Stem Cells (CCSCs) from Human Whole Blood.- Generation of Cancer Stem Cells by Co-Culture Methods.- Deep Learning of Cancer Stem Cell Morphology.

    Out of stock

    £161.99

  • PatientDerived Xenografts

    Humana PatientDerived Xenografts

    Out of stock

    Book Synopsis

    Out of stock

    £999.99

  • Molecular Biology of Cancer 2e

    John Wiley and Sons Ltd Molecular Biology of Cancer 2e

    1 in stock

    Book SynopsisThe Molecular Biology of Cancer, Stella Pelengaris & Michael Khan This capturing, comprehensive text, extensively revised and updated for its second edition, provides a detailed overview of the molecular mechanisms underpinning the development of cancer and its treatment. Bench to Bedside: A key strength of this book that sets it apart from general cancer biology references is the interweaving of all aspects of cancer biology from the causes, development and diagnosis through to the treatment and care of cancer patients essential for providing a broader view of cancer and its impact. The highly readable presentation of a complex field, written by an international panel of researchers, specialists and practitioners, would provide an excellent text for graduate and undergraduate courses in the biology of cancer, medical students and qualified practitioners in the field preparing for higher exams, and for researchers and teachers in the field. For thTrade Review“An excellent didactic technical production. For medical students, trainees, cancer biologists, oncologists, pharmacologists and endocrinologists. Cancer remains a menace in modern times.” (Pediatric Endocrinology Reviews, 1 September 2013) “This book will be invaluable for nursing and medical students, establishing a basic understanding and progressing to more complex issues. The end-of-chapter review questions are great preparation for exams.” (Nursing Standard, 1 September 2013Table of ContentsContributors vii Preface to the Second Edition ix Reviews of the First Edition x Acknowledgments and Dedication xi About the Companion Website xii Introduction 1 1 Overview of Cancer Biology 3 Michael Khan and Stella Pelengaris Introduction 5 Cancer incidence and epidemiology 8 Towards a definition of cancer 8 Causes of cancer 16 Cancer is a genetic disease 21 Cancers (and Darwin’s finches) evolve by mutation and natural selection 21 Blame the parents – inherited single gene defects and susceptibility to cancer 21 The cancer “roadmap” – What kinds of genes are epimutated in cancer? 23 Viruses and the beginnings of cancer biology 25 Hens and teeth or bears and woods? The hens have it – cancer is rare 25 The barriers to cancer 25 What is the secret of cancer developme . . . “timing” 28 Location location location – the cancer environment: nanny or spartan state 28 Cancer goes agricultural 29 Cancer superhighways – blood vessels and lymphatics 31 On your bike and turn the lights off before you go 31 Catching cancer 31 Hammering the hallmarks 32 Painting a portrait of cancer 33 The drugs don’t work 34 Mechanism of origin rather than cell of origin – towards a new functional taxonomy of cancer 35 Is it worth it? 36 Conclusions and future directions 36 Bibliography 37 Appendix 1.1 History of cancer 40 2 The Burden of Cancer 43 William P. Steward and Anne L. Thomas Introduction 43 Lung cancer 45 Breast cancer 49 Colorectal cancer 53 Carcinoma of the prostate 56 Renal carcinoma 57 Skin cancer 58 Carcinoma of the cervix 60 Hematological malignancies 60 Conclusions and future directions 63 Outstanding questions 63 Bibliography 64 Questions for student review 66 3 Nature and Nurture in Oncogenesis 67 Michael Khan and Stella Pelengaris Introduction 69 Risk factors 73 Preventing cancers 76 Cancer genetics – in depth 78 Cancer genomics 87 Gene–environment interactions 89 Mutations and treatment 89 Chemoprevention of cancer 90 Risk factors act in combination 90 Environmental causes of cancer 93 The clinical staging and histological examination of cancer 101 Screening and biomarkers 102 Somatic gene mutations epigenetic alterations and multistage tumorigenesis 105 Conclusions and future directions 107 Outstanding questions 107 Bibliography 107 Questions for student review 109 4 DNA Replication and the Cell Cycle 111 Stella Pelengaris and Michael Khan Introduction 112 The cell cycle – overview 114 Phases of the cell cycle 120 The cell-cycle engine: cyclins and kinases 123 Regulation by degradation 126 Regulation by transcription 129 MicroRNAs and the cell cycle 131 Chromatin 131 DNA replication and mitosis 131 Checkpoints – putting breaks on the cell-cycle The DNA damage response (DDR) 136 The checkpoints 136 Cell-cycle entry and its control by extracellular signals 138 Changes in global gene expression during the cell cycle 139 Cell cycle and cancer 139 Drugging the cell cycle in cancer therapies 141 Conclusions and future directions 142 Outstanding questions 143 Bibliography 143 Questions for student review 144 5 Growth Signaling Pathways and the New Era of Targeted Treatment of Cancer 146 Stella Pelengaris and Michael Khan Introduction 147 Growth factor regulation of the cell cycle 150 Growth homeostasis and tissue repair and regeneration 151 Regulated and deregulated growth 155 Cellular differentiation 157 Tissue growth and the “angiogenic switch” 158 Cancers and nutrients 158 Growth factor signaling pathways 160 A detailed description of signal transduction pathways and their subversion in cancer 160 Translational control and growth 184 Conclusions and future directions 185 Outstanding questions 185 Bibliography 186 Questions for student review 187 6 Oncogenes 188 Stella Pelengaris and Michael Khan Introduction 189 The oncogenes 189 The discovery of oncogenes ushers in the new era of the molecular biology of cancer 191 Overview of oncogenes 191 Types of oncogenes 193 Oncogene collaboration – from cell culture to animal models 199 The c-MYC oncogene 199 The RAS superfamily 213 SRC – the oldest oncogene 228 BCR–ABL and the Philadelphia chromosome 232 The BCL-2 family 235 Biologically targeted therapies in cancer and the concept of “oncogene addiction” 235 Conclusions and future directions 235 Outstanding questions 236 Bibliography 236 Questions for student review 238 7 Tumor Suppressors 239 Martine F. Roussel Introduction 239 The “two-hits” hypothesis: loss of heterozygosity (LOH) 240 Haploinsuffi ciency in cancer 240 Epigenetic events 242 Definition of a tumor suppressor 242 The retinoblastoma protein family 242 p53/TP53 250 INK4a/ARF 254 The p53 and RB pathways in cancer 257 Senescence and immortalization: Role of RB and p53 258 Tumor suppressors and the control of cell proliferation 258 Tumor suppressors and control of the DNA damage response and genomic stability 260 The microRNAs and tumor suppressors 260 Conclusions and future directions 263 Acknowledgments 263 Outstanding questions 264 Bibliography 264 Questions for student review 265 8 Cell Death 266 Stella Pelengaris and Michael Khan Introduction 267 An historical perspective 267 Apoptosis in context 267 Apoptosis as a barrier to cancer formation 271 Apoptosis versus necrosis 271 Cell death by necrosis – not just infl ammatory 272 The pathways to apoptosis 272 The apoptosome – “wheel of death” 274 Caspases – the initiators and executioners of apoptosis 274 The IAP family – inhibitors of apoptosis and much more 276 The central role of MOMP and its regulators in apoptosis – the BCL-2 family 279 Mitochondrial outer membrane permeabilization (MOMP) 281 Endoplasmic reticulum stress 282 Stress-inducible heat shock proteins 282 Tumor suppressor p53 282 Oncogenic stress: MYC-induced apoptosis 283 Autophagy – a different kind of cell death and survival 287 Cell death in response to cancer therapy 290 Exploiting cell death (and senescence) in cancer control 290 Conclusions and future directions 292 Outstanding questions 293 Bibliography 293 Questions for student review 294 9 Senescence Telomeres and Cancer Stem Cells 295 Maria A. Blasco and Michael Khan Introduction 296 Senescence 298 Conclusions and future directions 310 Outstanding questions 310 Bibliography 311 Questions for student review 312 10 Genetic Instability Chromosomes and Repair 314 Michael Khan Introduction 316 Telomere attrition and genomic instability 321 Sensing DNA damage 323 Repairing DNA damage 325 Checkpoints 336 Microsatellites and minisatellites 343 Chaperones and genomic instability 344 Cancer susceptibility syndromes involving genetic instability 345 Genomic instability and colon cancer 346 Conclusions and future directions 346 Outstanding questions 347 Bibliography 347 Questions for student review 349 11 There Is More to Cancer than Genetics: Regulation of Gene and Protein Expression by Epigenetic Factors Small Regulatory RNAs and Protein Stability 350 Stella Pelengaris and Michael Khan Introduction 351 The language of epigenetics 353 Epigenetics 353 Methylation of DNA 359 Acetylation of histones and other posttranslational modifications 360 Epigenetics and cancer 362 CIMP and MIN and the “mutator phenotype” 365 Imprinting and loss of imprinting 366 Clinical use of epigenetics 367 Regulation of translation 368 Noncoding RNA and RNA interference 369 Therapeutic and research potential of RNAi 371 Treatments based on miRNA 373 Regulating the proteins 373 Therapeutic inhibition of the proteasome 376 Receptor degradation 377 Wrestling with protein transit – the role of SUMO and the promyelocytic leukemia (PML) body 377 Conclusions and future directions 380 Outstanding questions 380 Bibliography 381 Questions for student review 382 12 Cell Adhesion in Cancer 383 Charles H. Streuli Introduction 383 Adhesive interactions with the extracellular matrix 384 Cell–cell interactions 393 Critical steps in the dissemination of metastases 395 E-cadherin downregulation in cancer leads to migration 399 Epithelial–mesenchymal transitions 401 Integrins metalloproteinases and cell invasion 402 Survival in an inappropriate environment 404 Conclusions 406 Outstanding questions 406 Bibliography 407 Questions for student review 409 13 Tumor Immunity and Immunotherapy 410 Cassian Yee Introduction 410 Endogenous immune response 411 Effector cells in tumor immunity 413 Tumor antigens 417 Antigen-specific therapy of cancer 420 Clinical trials in vaccine therapy 422 Cytokine therapy of cancer 423 Tumor immune evasion 424 Clinical trials in immunomodulatory therapy 425 Conclusions 425 Bibliography 426 Questions for student review 427 14 Tumor Angiogenesis 429 Christiana Ruhrberg Introduction 429 General principles of new vessel growth 430 Pathological neovascularization: tumor vessels 430 Basic concepts in tumor angiogenesis: the angiogenic switch 432 Vascular growth and differentiation factors: stimulators of the angiogenic switch 432 Role of inhibitors in angiogenesis 436 Clinical outcomes and future directions 436 Acknowledgments 437 Bibliography 437 Questions for student review 437 15 Cancer Chemistry: Designing New Drugs for Cancer Treatment 438 Ana M. Pizarro and Peter J. Sadler Introduction 439 Historical perspective 439 The drug discovery process and preclinical development of a drug 442 Questions remaining 457 Conclusions and future directions 457 Bibliography 458 Questions for student review 459 16 Biologically Targeted Agents from Bench to Bedside 461 Michael Khan Peter Sadler Ana M. Pizarro and Stella Pelengaris Introduction 463 Targeted therapies 465 Cancer cell heterogeneity 466 Finding the molecular targets 468 Tumor regression in mice by inactivating single oncogenes 468 Targeted cancer therapies 473 Targeting oncogenes to treat cancer? 473 The concept of synthetic lethality and collateral vulnerability 475 Clinical progress in biological and molecular targeted therapies 476 Molecular targeted drugs – an inventory 479 DNA damage responses 490 Transcription factors 491 Targeting epigenetic regulation of gene expression 492 Hitting the extrinsic support network and preventing spread 493 Gene therapy antisense and siRNA 495 Resistance to targeted therapies – intrinsic resistance and emergence of secondary pathways and tumor escape 497 Negative feedback loops and failure of targeted therapies 500 Biomarkers to identify optimal treatments and tailored therapies 501 Pharmacogenetics and pharmacogenomics 505 Clinical trials in cancer 506 Conclusions and future directions 506 Bibliography 507 Questions for student review 508 17 The Diagnosis of Cancer 509 Anne L. Thomas Bruno Morgan and William P. Steward Introduction 509 Clinical manifestations 510 Investigations in oncological practice 511 Non-invasive imaging techniques 516 Future novel uses of imaging 521 Proteomics and microarrays 523 Circulating tumor cells 523 Disease staging 523 Conclusions and future directions 524 Bibliography 524 Questions for student review 525 18 Treatment of Cancer: Chemotherapy and Radiotherapy 526 Anne L. Thomas J.P. Sage and William P. Steward Introduction 526 Radiotherapy physics 526 Radiobiology 527 Treatment planning 528 Recent advances 529 Chemoradiation 530 Conclusion 540 Bibliography 542 Questions for student review 543 19 Caring for the Cancer Patient 544 Nicky Rudd and Esther Waterhouse Introduction 544 Key concepts 544 Communication with the cancer patient 544 When is palliative care appropriate for cancer patients? 545 Palliative care assessment 545 Symptom control 545 Respiratory symptoms 547 Nausea and vomiting 547 Bowel obstruction 548 Constipation 549 Fatigue 549 Cachexia and anorexia 549 Psychological problems 549 The dying patient 550 Supportive care 550 An example of the care of a cancer patient 551 Questions remaining 551 Conclusions and future directions 551 Underlying problems 551 Comment 551 Underlying problems 552 Bibliography 552 Questions for student review 553 20 Systems Biology of Cancer 554 Walter Schubert Norbert C.J. de Wit and Peter Walden Introduction 556 Information flow in cells 556 Model organisms and cancer models 557 Array-based technologies: genomics epigenomics and transcriptomics 559 SNPs the HapMap and the identification of cancer genes 559 Cancer mRNA expression analysis 562 CGH arrays CpG island microarrays and ChIP-on-Chip 564 Next-generation sequencing 564 Proteomics 566 Posttranslational modifi cations 567 Protein complexes and cellular networks 569 Clinical applications of proteomics 570 Toponomics: investigating the protein network code of cells and tissues 571 Processing the images from the cyclical imaging procedures 571 Structure code and semantics of the toponome: a high-dimensional combinatorial problem 573 Detecting a cell surface protein network code: lessons from a tumor cell 575 The molecular face of cells in diseases 576 Individualized medicine and tailored therapies 576 Discussion and conclusion 579 Bibliography 579 Internet resources 581 Questions for student review 582 Appendix 20.1 Techniques for the generation of genetically altered mouse models of cancer 582 Glossary 585 Answers to Questions 597 Index 603

    1 in stock

    £83.66

  • Lung Cancer

    John Wiley and Sons Ltd Lung Cancer

    15 in stock

    Book SynopsisLung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. This book provides the research in the identification of biomarkers to predict a high risk for developing lung cancer.Trade Review“With almost half of the revised and updated content being brand new, Lung Cancer, Fourth Edition, is an important and vital resource for all medical professionals and students involved in the care and treatment of those struck with this catastrophic illness.” (Kingbook73's Medical Ebook and Video Collection, 19 September 2014) Table of ContentsContributors, viii Preface, xiii 1 Smoking Prevention and Cessation, 1Alexander V. Prokhorov and Karen Suchanek Hudmon 2 Lung Cancer Susceptibility and Risk Assessment Models, 25Xifeng Wu, Xia Pu, and Jie Lin 3 Molecular Profiling, 48Lauren Averett Byers 4 Somatic Genome Alterations in Human Lung Cancers, 67Marcin Imielinski, Peter S. Hammerman, Roman Thomas, and Matthew Meyerson 5 Serum Proteomic Biomarkers, 90Mohamed Hassanein and David P. Carbone 6 Molecular Biology of Lung Preneoplasia, 110Humam Kadara and Ignacio I. Wistuba 7 Detection and Treatment of Preneoplastic Lesions, 129Rachel Jen and Stephen Lam 8 Pathology of Adenocarcinoma, 144William D. Travis 9 Management of Multifocal Bronchioloalveolar Carcinoma (BAC), 158Howard West 10 Radiology and Lung Cancer Screening, 176Patricia de Groot and Reginald F. Munden 11 Imaging Lung Cancer, 191Sonia L. Betancourt Cuellar, Edith M. Marom, and Jeremy J. Erasmus 12 Staging of the Mediastinum, 202Mauricio Pipkin and Shaf Keshavjee 13 Management of the Solitary Pulmonary Nodule, 214Min P. Kim 14 Minimally Invasive Resections for Lung Cancer, 224Shanda H. Blackmon 15 Extended Resections for Lung Cancer, 236Matthew A. Steliga and David C. Rice 16 Bronchoscopic Interventions for Lung Cancer, 253Donald R. Lazarus and George A. Eapen 17 Primary Tracheal Tumors, 267Francesco Sammartino and Paolo Macchiarini 18 Adjuvant Chemotherapy Following Surgery for Lung Cancer, 278Kathryn A. Gold 19 Neoadjuvant Chemotherapy for Resectable Non-Small Cell Lung Cancer, 290Christopher G. Azzoli and Katherine M.W. Pisters 20 Image-Guided Radiation Therapy, 309Kenneth E. Rosenzweig and Sonal Sura 21 Stereotactic Ablative Radiotherapy for Lung Cancer, 320Puneeth Iyengar and Robert D. Timmerman 22 Proton Therapy, 338Joe Y. Chang and James D. Cox 23 Combinations of Radiation Therapy and Chemotherapy for Non-small Cell and Small-Cell Lung Carcinoma, 353Daniel Gomez, Zhongxing Liao, Pierre Saintigny, and Ritsuko U. Komaki 24 Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non-small Cell Lung Cancer, 379Heath D. Skinner, Ritsuko U. Komaki, Joe Y. Chang, and James D. Cox 25 Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer, 390Steven H. Lin and Ritsuko U. Komaki 26 EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review, 406Kathryn F. Mileham, Edward S. Kim, and William N. William Jr 27 Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non-small Cell Lung Cancer, 421Erminia Massarelli 28 Predictive Tumor Biomarkers for EGFR Inhibitors, 435Lucia Kim, Geoffrey Liu, and Ming-Sound Tsao 29 Immunologic Approaches to Lung Cancer Therapy, 454Jay M. Lee, Steven M. Dubinett, and Sherven Sharma 30 Novel and Emerging Agents in NSCLC, 464Anne S. Tsao and Jack A. Roth 31 Novel Clinical Trial Designs for Metastatic Lung Cancer, 479Vassiliki A. Papadimitrakopoulou 32 Novel Statistical Models for NSCLC Clinical Trials, 488J. Jack Lee and Caleb T. Chu 33 Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy, 505John V. Heymach and Tina Cascone 34 Anti-angiogenic Agents in Metastatic NSCLC, 527Millie Das and Heather Wakelee 35 Targeting ALK Rearrangements, 541Justin F. Gainor and Alice T. Shaw 36 Non-small Cell Lung Cancers (NSCLC) with Mutations in BRAF, 557Renata Ferrarotto and George R. Simon 37 Prognostic and Predictive Biomarker Signatures, 564Johannes R. Kratz and David M. Jablons 38 Brain Metastasis from Lung Cancer, 572Ritsuko U. Komaki and Amol J. Ghia Index, 591 Color plate section between pages 146 and 147

    15 in stock

    £145.76

  • Management of Urologic Cancer

    John Wiley and Sons Ltd Management of Urologic Cancer

    1 in stock

    Book SynopsisManaging urologic cancer by preserving, as opposed to removing, affected tissue, is rapidly becoming the favoured choice for urologists and oncologists. Discover all available options and how to achieve the best possible patient management with this expert guide to the area. The editor, Mark Schoenberg, is an internationally-renown expert in this exciting new area and has recruited an outstanding team featuring some of the leading urologists/oncologists in North America and Europe to assist him.Table of ContentsList of Contributors xiii Preface xvii Cancer Genetics, Cancer Biology, and Tumor Growth and Metastasis: The Interaction of Cancer and Its Host Environment 1Mark C. Markowski and Kenneth J. Pienta Renal Cell Carcinoma 1 Bladder Cancer 3 Prostate Cancer 6 References 12 Pathological Basis of Tumor Characterization: Cytopathology, Surgical Pathology, and How Histo]Morphology Informs Treatment Decision Making 19Oleksandr N. Kryvenko and Fadi Brimo The Kidney 23 The Urothelium 27 The Testis 29 References 30 The Immunobiology of Tumor Ablation 33Rafi Kabarriti and Chandan Guha Manipulating the Immune System to Fight Cancer 33 Can We Take Advantage of Ablative Therapies to Activate the Immune System? 34 Immunomodulatory Properties of HIFU 35 Immunomodulatory Properties of Cryotherapy 36 Immunomodulatory Properties of Radiation Therapy 37 References 38 Computed Tomography of Urologic Malignancies: The Role of MDCT in Renal Cell Carcinoma and Transitional Cell Carcinoma 41Siva P. Raman and Elliot K. Fishman Introduction 41 MDCT Protocol Design 41 Three]Dimensional Reconstructions 44 Neoplasms of the Intrarenal Collecting Systems, Ureters, and Bladder 45 Solid Renal Parenchymal Lesions 49 Conclusion 55 References 55 MRI and Metabolic Imaging 59Louise Dickinson, Francesco Fraioli, Athar Haroon, and Clare Allen Magnetic Resonance Imaging 59 MRI Sequences 59 Clinical Applications of MRI for Prostate Cancer 61 Clinical Applications of MRI for Renal Cancer 63 Clinical Applications of MRI for Bladder Cancer 64 New Advances in MRI 65 Metabolic Imaging 66 Clinical Applications of PET–CT for Prostate Cancer 69 Active Surveillance for Low]Risk Prostate Cancer 113Laurence Klotz Introduction and Background 113 Rationale 113 Genetic Features of Low]Grade Prostate Cancer 114 Metastatic Potential 115 Limitations of PSA Kinetics 116 Role of MRI 116 Implications for Patient Management 117 Eligibility for Surveillance 118 Outcome of Surveillance 119 Modeling 119 AS in Practice 121 Conclusions 121 References 122 Tissue]Preserving Surgical Approaches in Urologic Oncology: The Therapeutic Mechanism for Tumor Ablation 127Ganesh Kartha and J. Stephen Jones Introduction 127 Cryoablation: Extreme Cold for Tumor Necrosis 128 Conclusion 130 References 130 Focal Therapy for Prostate Cancer: An Evidence]Based Approach to Tissue]Preserving Strategies 133Kara L. Watts, Yaalini Shanmugabavan, Victoria Chernyak, and Hashim Uddin Ahmed Introduction 133 Key Concepts in FT for PCa 134 Tissue]Preserving FTs 135 Cryotherapy 135 HIFU 137 Salvage Focal/Hemiablation HIFU 140 IRE 141 Radiation 142 Additional Therapies 143 Implications for Research 144 Conclusions 144 References 145 The Modern Basis for Nephron]Sparing Surgery in Patients with Renal Cancer: Biologic Heterogeneity, the Significance of Tumor Biopsy, and the Changing Roles of Partial Nephrectomy and Tumor Ablation 151Jeffrey J. Tomaszewski, Robert G. Uzzo, and David Y.T. Chen Introduction 151 Principal Treatment Options for SRMs and the Basis for Nephron Preservation 152 Comparative Effectiveness of Radical versus NSS 153 Rationale for Ablative Therapies 154 Treatment Trends for Stage I RCC 157 The Role of RMB 158 Challenges Posed by Intratumoral Heterogeneity 161 Conclusions 161 References 162 Bladder]Preserving Strategies in the Treatment of Urothelial Cancer: The Disease Spectrum and the Dawn of Molecular Surgical Guidance 169Stephan Kruck and Arnulf Stenzl Augmented Cystoscopy 170 Fiber]Optic Probe Technology 171 Conclusion 172 References 172 Image]Guided Thermal Ablation of Adrenal Malignancies 175Kyungmouk Steve Lee, Bradley B. Pua, and Stephen B. Solomon Introduction 175 Clinical Results 175 Preprocedural Evaluation 176 Technical Considerations 178 RFA 178 Microwave Ablation 179 Cryoablation 180 Complications 180 Follow]up 181 Conclusion 182 References 182 Managing Penile Cancer: Integrating Tissue Preservation, Energy]Based Therapeutics, and Surgical Reconstruction 185Arthur L. Burnett Introduction 185 Description 186 Diagnosis and Staging 186 Treatment 189 References 193 Testis Cancer: Testis]Sparing Cancer Surgery 199Nilay M. Gandhi and Pravin K. Rao Introduction 199 Imaging of Testicular Tumors 199 Bilateral Tumors 201 The Advent of Testis]Sparing Surgery 201 Concerns about TSS 201 Indications for TSS 204 Preoperative Considerations and Surgical Technique 204 Postoperative Care and Follow]Up 207 Considerations Regarding Surgical Technique 207 Outcomes of TSS 208 Summary 209 References 210 Nanotechnology: An Evolution in Tissue Preservation and Focal]Targeted Oncologic Therapy 213Kara L. Watts and Joshua M. Stern Introduction 213 Introduction to Nanotechnology 214 Types of Nanoparticles 214 Delivery and Use of Nanoparticles 217 Nanotechnology in Prostate Cancer 219 Imaging in Prostate Cancer 219 Therapeutics in Prostate Cancer 221 Nanotechnology in Renal Cancer 223 Nanotechnology in Other Urologic Cancers 224 Limitations of Nanoparticles 224 Future Directions and Conclusions 225 References 226 Trial Design Issues in the Study of Focal Therapy in Prostate and Kidney Cancer 233John B. Eifler and David F. Penson Issues around Endpoints in Studies of Focal Therapy 234 Issues around Defining the Study Population and the Control Arms of Comparative Studies in Focal Therapy 237 Issues around Selecting the Optimal Study Design in Focal Therapy 238 Conclusion 238 References 239 Index 000

    1 in stock

    £117.85

  • John Wiley and Sons Ltd Mindfulness

    Out of stock

    Book SynopsisMindfulness: A Kindly Approach to Being with Cancer offers people with cancer a means to bring mindfulness and kindliness into their lives, to help them cope with the challenge of a life-threatening illness. Adapts Mindfulness-Based Cognitive Therapy (MBCT), an approach with a strong evidence base for people with recurrent depression, for the needs and challenges of people with cancer Presents the standard 8-week course of MBCT for cancer in a flexible format that is designed to suit each reader's own particular timescale, context and situation Based on more than 15 years of program development and clinical application by the author, and the work and experience of mindfulness teachers in other cancer centres around the world Provides specific practices and approaches tailored to support the different phases of a cancer experience from diagnosis and treatment to living with uncertainty and managing life with cancer Features fivTrade Review "A diagnosis of cancer can produce waves of shock, confusion and despair affecting not only the sufferer, but also family and close friends. Where can you turn? What resources can you find right now that will ease the pain? From start to finish, trish bartley provides the best sort of support for anyone suffering such anguish. Here is not only something to read, but something to practice."—Mark Williams, Emeritus Professor of Clinical Psychology, Oxford Mindfulness Centre, University of Oxford, UK "How do we skillfully meet suffering with kindness? Trish has distilled her years of experience into this wonderfully clear and accessible guide to mindfulness. An embodiment of compassion and wisdom, and an inspiring read."—Rebecca Crane, Director, Centre for Mindfulness Research and Practice, Bangor University, ULK "This is a lovely book – wise, compassionate, and very practical. Here is a wonderful friendly guide to tried and tested ways to live more fully and kindly with cancer."—John Teasdale, Research Scientist, Medical Research Council, Cambridge, UK Table of Contents Acknowledgments ix About the Companion Website xi Some Opening Words 3 Starting Out 5 1 Intention 21 Intention Theme 22 The Practices 33 Experience of Cancer – Diagnosis 45 Personal Story – Sarah 55 2 Coming Back 60 Coming Back Theme 61 The Practices 72 Experience of Cancer – Treatment 97 Personal Story – Caroline 112 3 Turning Towards 117 Turning Towards Theme 118 The Practices 131 Experience of Cancer – Remission / Living with Uncertainty 152 Personal Story – Peter 160 4 Kindness 165 Kindness Theme 167 The Practices 176 Experience of Cancer – Recurrence 201 Personal Story – Jane 211 5 Completing And Continuing 217 Personal Story – Helen 234 6 Connecting To Our Common Humanity 240 Some Parting Words 250 Appendices 254 1 Cancer And Mindfulness]Based Approaches 254 2 Resources 256 3 The ‘Map’ of Mindfulness-Based Cognitive Therapy for Cancer 259 4 Lee’s Soups 261 Bibliography 265 Index 269 About the Author

    Out of stock

    £54.71

  • Translational Toxicology and Therapeutics

    John Wiley & Sons Inc Translational Toxicology and Therapeutics

    1 in stock

    Book SynopsisWritten by leading research scientists, this book integrates current knowledge of toxicology and human health through coverage of environmental toxicants, genetic / epigenetic mechanisms, and carcinogenicity. Provides information on lifestyle choices that can reduce cancer risk Offers a systematic approach to identify mutagenic, developmental and reproductive toxicants Helps readers develop new animal models and tests to assess toxic impacts of mutation and cancer on human health Explains specific cellular and molecular targets of known toxicants operating through genetic and epigenetic mechanisms Table of ContentsList of Contributors xix Part One Introduction: The Case for Concern about Mutation and Cancer Susceptibility during Critical Windows of Development and the Opportunity to Translate Toxicology into a Therapeutic Discipline 1 1 What Stressors Cause Cancer and When? 3Claude L. Hughes and Michael D. Waters 1.1 Introduction 3 1.1.1 General Information about Cancer 5 1.1.2 Stressors and Adaptive Responses 8 1.2 What Stressors Cause Cancer and When? 8 1.2.1 Mutagenic MOAs 13 1.2.1.1 DNA Repair 14 1.2.2 Epigenetic MOAs 16 1.2.3 Nongenotoxic Carcinogens, ROS, Obesity, Metabolic, Diet, Environment, Immune, Endocrine MOAs 20 1.2.4 Tumor Microenvironment MOAs 25 1.3 Relevance of Circulating Cancer Markers 26 1.4 Potential Cancer Translational Toxicology Therapies 29 1.4.1 Well-Established/Repurposed Pharmaceuticals 31 1.4.2 GRAS/GRASE, Diet, and Nutraceuticals 34 1.4.2.1 Suppression of Cell Proliferation and Induction of Cell Death 35 1.4.2.2 Anti-Inflammatory Effects: Insights from Various Diseases 36 1.4.2.3 Upregulation of Tumor Suppressor MicroRNAs 38 1.4.2.4 Regulation of Oxidative Stress 38 1.4.2.5 Activation of Signal Transduction Pathways 39 1.4.2.6 Mitigating Inherited Deleterious Mutations 40 1.4.2.7 Mitigating Adverse Epigenetic States 42 1.4.2.8 Paradigm for Study of Cancer Chemoprevention 43 1.5 Modeling and the Future 47 References 51 2 What Mutagenic Events Contribute to Human Cancer and Genetic Disease? 61Michael D. Waters 2.1 Introduction 61 2.1.1 Childhood Cancer, Developmental Defects, and Adverse Reproductive Outcomes 62 2.1.2 Newborn Screening for Genetic Disease 62 2.1.3 Diagnosis of Genetic Disease 63 2.1.4 Familial and Sporadic Cancer 65 2.2 Genetic Damage from Environmental Agents 67 2.3 Testing for Mutagenicity and Carcinogenicity 71 2.4 Predictive Toxicogenomics for Carcinogenicity 73 2.5 Germ Line Mutagenicity and Screening Tests 76 2.6 Reproductive Toxicology Assays in the Assessment of Heritable Effects 80 2.6.1 Segmented Reproductive Toxicity Study Designs 80 2.6.2 Continuous Cycle Designs 81 2.6.2.1 One-Generation Toxicity Study 81 2.6.2.2 Repeat Dose Toxicity Studies 82 2.7 Assays in Need of Further Development or Validation 82 2.7.1 Transgenic Rodent Gene Mutation Reporter Assay 82 2.7.2 Expanded Simple Tandem Repeat Assay 84 2.7.3 Spermatid Micronucleus (MN) Assay 85 2.7.4 Sperm Comet Assay 86 2.7.5 Standardization of Sperm Chromatin Quality Assays 86 2.8 New Technologies 87 2.8.1 Copy Number Variants and Human Genetic Disease 87 2.8.2 Next-Generation Whole Genome Sequencing 88 2.8.3 High-Throughput Analysis of Egg Aneuploidy in C. elegans, and Other Alternative Assay Systems 90 2.9 Endpoints Most Relevant to Human Genetic Risk 91 2.10 Worldwide Regulatory Requirements for Germ Cell Testing 94 2.11 Conclusion 95 Acknowledgments 96 References 96 3 Developmental Origins of Cancer 111Suryanarayana V. Vulimiri and John M. Rogers 3.1 Introduction 111 3.2 Current Trends in Childhood Cancer 112 3.3 Potential Mechanisms of Prenatal Cancer Induction 113 3.4 Ontogeny of Xenobiotic Metabolizing Enzymes and DNA Repair Systems 113 3.5 The Developmental Origins of Health and Disease (DOHaD) Theory 115 3.6 Epigenetic Regulation during Development 115 3.6.1 Critical Periods for Epigenetic Regulation 116 3.7 Mechanisms of Cancer in Offspring from Paternal Exposures 117 3.8 Parental Exposures Associated with Cancer in Offspring 118 3.8.1 Radiation 118 3.8.2 Diethylstilbestrol 119 3.8.3 Tobacco Smoke 120 3.8.4 Pesticides 122 3.8.5 Arsenic 123 3.9 Models for the Developmental Origins of Selected Cancers 124 3.9.1 Breast Cancer 124 3.9.2 Leukemia 127 3.10 Public Health Agencies’ Views on Prenatal Exposures and Cancer Risk 129 3.10.1 The United States Environmental Protection Agency (US EPA) 129 3.10.2 The California Environmental Protection Agency (CalEPA) 131 3.10.3 Washington State Department of Ecology (WA DoE) 133 3.11 Conclusions 134 Acknowledgment 135 References 135 4 The Mechanistic Basis of Cancer Prevention 147Bernard W. Stewart 4.1 Introduction 147 4.2 A Mechanistic Approach 147 4.2.1 Specifying Carcinogens 148 4.2.2 Cancer Risk Factors Without Carcinogen Specification 148 4.3 Preventing Cancer Attributable to Known Carcinogens 149 4.3.1 Involuntary Exposure 149 4.3.1.1 Infectious Agents 149 4.3.1.2 Occupation 150 4.3.1.3 Drugs 151 4.3.1.4 Pollution 152 4.3.1.5 Dietary Carcinogens 152 4.3.2 Tobacco Smoking 153 4.3.2.1 Measures to Limit Availability and Promotion 154 4.3.2.2 Product Labeling, Health Warnings, and Usage Restrictions 154 4.3.2.3 Smoking Cessation 155 4.3.3 Alcohol Drinking 155 4.3.4 Solar and Ultraviolet Radiation 156 4.4 Prevention Involving Complex Risk Factors 157 4.4.1 Workplace Exposures 157 4.4.2 Diet and Overweight/Obesity 157 4.5 Prevention Independent of Causative Agents or Risk Factors 158 4.5.1 Screening 158 4.5.2 Chemoprevention 159 4.6 Conclusion 160 References 160 Part Two Exposures that Could Alter the Risk of Cancer Occurrence, and Impact Its Indolent or Aggressive Behavior and Progression Over Time 171 5 Diet Factors in Cancer Risk 173Lynnette R. Ferguson 5.1 Introduction 173 5.2 Obesity 174 5.3 Macronutrients 175 5.3.1 Protein 176 5.3.2 Lipids 177 5.3.3 Carbohydrates 178 5.4 Micronutrients 181 5.4.1 Vitamins 181 5.4.2 Minerals 184 5.5 Phytochemicals 184 5.5.1 Phytoestrogens 185 5.5.2 Other Phytochemicals 186 5.6 Conclusions 188 References 188 6 Voluntary Exposures: Natural Herbals, Supplements, and Substances of Abuse – What Evidence Distinguishes Therapeutic from Adverse Responses? 199Eli P. Crapper, Kylie Wasser, Katelyn J. Foster, and Warren G. Foster 6.1 Introduction 199 6.1.1 Alcohol 200 6.1.2 Cigarette Smoking 201 6.1.3 Herbals and Supplements 202 6.1.3.1 Melatonin 202 6.1.3.2 Resveratrol 204 6.1.3.3 Dong Quai 205 6.1.3.4 Eleutherococcus 206 6.1.3.5 Saw Palmetto 206 6.1.3.6 Stinging Nettle 207 6.2 Summary and Conclusions 207 References 207 7 Voluntary Exposures: Pharmaceutical Chemicals in Prescription and Over-the-Counter Drugs – Passing the Testing Gauntlet 213Ronald D. Snyder 7.1 Introduction 213 7.2 Testing of New Drug Entities for Genotoxicity 214 7.3 Relationship between Genotoxicity Testing and Rodent Carcinogenicity 217 7.4 Can Drug-Induced Human Cancer Be Predicted? 218 7.5 What Can Rodent Carcinogenicity Tell Us about Human Cancer Risk? 220 7.6 Genotoxicity Prediction Using “Traditional” In Silico Approaches 222 7.7 Covalent versus Noncovalent DNA Interaction 223 7.8 Use of New Technologies to Predict Toxicity and Cancer Risk: High-Throughput Methods 224 7.9 Transcriptomics 225 7.10 Single-Nucleotide Polymorphisms (SNPs) 226 7.11 Conclusions 227 Appendix A 228 References 253 8 Children’s and Adult Involuntary and Occupational Exposures and Cancer 259Annamaria Colacci and Monica Vaccari 8.1 Introduction 259 8.2 Occupational Exposures and Cancer 262 8.2.1 Occupational Cancer in the Twenty-First Century 262 8.2.2 Past and Present Occupational Exposure to Asbestos 263 8.2.3 Toxicology of Fibers: What We Have Learned from the Asbestos Lesson 265 8.2.3.1 Mechanism and Mode of Action of Asbestos and Asbestos-Like Fibers in Carcinogenesis: The Role of Inflammation and Immune System to Sustain the Cancer Process 268 8.2.4 Occupational Exposures and Rare Tumors 270 8.3 Environmental Exposures and Cancer 271 8.3.1 Environmental Exposures and Disease: Is This the Pandemic of the Twenty-First Century? 271 8.3.2 The Complexity of Environmental Exposures 272 8.3.3 Environmental Impact on Early Stages of Life: Are Our Children at Risk? 274 8.3.4 Environmental Endocrine Disruptors: The Steps Set Out to Recover Our Stolen Future 277 8.3.5 From Occupational to Environmental Exposures: Asbestos and Other Chemicals of Concern 279 8.3.5.1 Asbestos 279 8.3.5.2 Arsenic and Arsenic Compounds 280 8.3.5.3 Phthalates 282 8.3.5.4 Pesticides 283 8.3.5.5 Mycotoxins 286 8.3.6 Air Pollution and Airborne Particulate Matter: The Paradigmatic Example of Environmental Mixtures 288 8.3.6.1 Characteristics of PM and PM Exposures 289 8.3.6.2 PM Exposures and Cancer 291 8.3.6.3 Possible Mechanisms of PM Toxicity 293 8.3.6.4 The Role of PM Exposures in the Fetal Origin of the Disease 294 8.4 Conclusions and Future Perspectives 296 References 299 Part Three Gene–Environment Interactions 317 9 Ethnicity, Geographic Location, and Cancer 319Fengyu Zhang 9.1 Introduction 319 9.2 Classification of Cancer 320 9.2.1 Classification by Histology 320 9.2.2 Classification by Primary Location 322 9.3 Ethnicity and Cancer 323 9.3.1 Cancer Death and Incidence 323 9.3.2 Site-Specific Cancer Incidence 326 9.3.3 Site-Specific Cancer Incidence between the United States and China 328 9.4 Geographic Location and Cancer 331 9.4.1 Mapping Human Diseases to Geographic Location 331 9.4.2 Geographic Variation and Cancer in the United States 332 9.5 Ethnicity, Geographic Location, and Lung Cancer 334 9.5.1 Ethnic Differences 334 9.5.2 Geographic Variation 335 9.5.3 Individual Risk Factors 335 9.6 Common Cancers in China 338 9.6.1 Liver Cancer 339 9.6.1.1 Geographic Variation 339 9.6.1.2 Urban Residence and Sex 340 9.6.1.3 Hepatitis B Virus Infection 340 9.6.1.4 Familial Aggregation and Genetic Variants 341 9.6.2 Gastric Cancer 342 9.6.2.1 H. pylori 342 9.6.2.2 Familial Aggregation 343 9.6.2.3 Genetic Susceptibility Factors 343 9.6.3 Esophageal Cancer 344 9.6.3.1 Geographic Variation 344 9.6.3.2 Viral Infections 344 9.6.3.3 Familial Aggregation 345 9.6.3.4 Genetic Susceptibility Factors 345 9.6.4 Lung Cancer 346 9.6.5 Genetic Susceptibility Factors 347 9.6.6 Cervical Cancer 348 9.7 Cancer Risk Factors and Prevention 348 9.7.1 Environmental Chemical Exposure 348 9.7.2 Infectious Agents 349 9.7.3 Psychosocial Stress and Social Network 349 9.7.4 The Developmental Origin of Adult-Onset Cancer 350 9.7.5 Cancer Prevention and Intervention 351 References 353 10 Dietary/Supplemental Interventions and Personal Dietary Preferences for Cancer: Translational Toxicology Therapeutic Portfolio for Cancer Risk Reduction 363Sandeep Kaur, Elaine Trujillo, and Harold Seifried 10.1 Introduction 363 10.2 Gene Expression and Epigenetics 364 10.3 Environmental Lifestyle Factors Affecting Cancer Prevention and Risk 366 10.3.1 Obesity 366 10.3.2 Weight Loss 368 10.3.3 Physical Activity 369 10.4 Dietary Patterns 370 10.5 Complementary and Integrative Oncology Interventions/Restorative Therapeutics 373 10.6 Special and Alternative Diets 377 10.7 Popular Anticancer Diets 378 10.7.1 Macrobiotic Diet 378 10.7.2 The Ketogenic Diet 382 10.7.3 Fasting Diet 383 10.8 Conclusion 384 Acknowledgment 384 References 385 11 Social Determinants of Health and the Environmental Exposures: A Promising Partnership 395Lauren Fordyce, David Berrigan, and Shobha Srinivasan 11.1 Introduction 395 11.1.1 Conceptual Model 397 11.1.2 Difference versus Disparity 398 11.2 Social Determinants of Health 399 11.2.1 Race/Ethnicity 399 11.2.2 Social Determinants of Health: “Place” and Its Correlates 402 11.2.3 Gender and Sexuality 405 11.3 Conclusions: Social Determinants of Health and Windows of Susceptibility 407 Acknowledgments 408 References 408 Part Four Categorical and Pleiotropic Nonmutagenic Modes of Action of Toxicants: Causality 415 12 Bisphenol A and Nongenotoxic Drivers of Cancer 417Natalie R. Gassman and Samuel H. Wilson 12.1 Introduction 417 12.2 Dosing 420 12.3 Receptor-mediated Signaling 421 12.4 Epigenetic Reprogramming 422 12.5 Oxidative stress 424 12.6 Inflammation and Immune Response 425 12.7 BPA-Induced Carcinogenesis 426 12.8 Fresh Opportunities in BPA Research 428 References 429 13 Toxicoepigenetics and Effects on Life Course Disease Susceptibility 439Luke Montrose, Jaclyn M. Goodrich, and Dana C. Dolinoy 13.1 Introduction to the Field of Toxicoepigenetics 439 13.1.1 The Epigenome 440 13.1.2 Epigenetic Marks are Heritable and Reversible 440 13.1.3 DNA Methylation 441 13.1.4 Histone Modifications and Chromatin Packaging 442 13.1.5 Noncoding RNAs 443 13.1.6 Key Windows for Exposure-Related Epigenetic Changes 443 13.1.7 Evaluation of Environmentally Induced Epigenetic Changes in Animal Models and Humans 444 13.2 Exposures that Influence the Epigenome 444 13.2.1 Air Pollution 445 13.2.2 Metals 447 13.2.3 Endocrine Disrupting Chemicals (EDCs) 448 13.2.4 Diet 451 13.2.5 Stress 453 13.3 Intergenerational Exposures and Epigenetic Effects 454 13.4 Special Considerations and Future Directions for the Field of Toxicoepigenetics 456 13.4.1 Tissue Specificity 456 13.4.2 The Dynamic Nature of DNA Methylation 458 13.5 Future Directions 459 13.6 Conclusions 460 Acknowledgments 461 References 461 14 Tumor-Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons 473William H. Bisson, Amedeo Amedei, Lorenzo Memeo, Stefano Forte, and Dean W. Felsher 14.1 Introduction 473 14.2 The Immune System 475 14.2.1 Innate Immune Response 475 14.2.2 Adaptive Immune Response 478 14.3 Prioritized Chemicals 482 14.3.1 Bisphenol A 482 14.3.2 Polybrominated Diphenyl Ethers 483 14.3.3 4-Nonylphenol 485 14.3.4 Atrazine 485 14.3.5 Phthalates 486 14.4 Experimental Models of Carcinogenesis through Inflammation and Immune System Deregulation 487 14.5 Antioxidants and Translational Opportunities 493 14.6 Tumor Control of the Microenvironment 495 Acknowledgments 497 References 497 15 Metabolic Dysregulation in Environmental Carcinogenesis and Toxicology 511R. Brooks Robey 15.1 Introduction 511 15.2 Metabolic Reprogramming and Dysregulation in Cancer 513 15.2.1 Carbohydrate Metabolism in Cancer 515 15.2.2 Lipid Metabolism in Cancer 519 15.2.3 Protein Metabolism in Cancer 521 15.3 Moonlighting Functions 523 15.4 Cancer Metabolism in Context 523 15.4.1 The Gestalt of Intermediary Metabolism 523 15.4.2 Cancer Tissues, Cells, and Organelles as Open Systems 527 15.4.3 The Endosymbiotic Nature of Cancer 527 15.4.4 Catabolic and Anabolic Support of Cell Proliferation 528 15.4.5 Cancer Heterogeneity 529 15.4.6 Phenotypic Relationships between Cancer Cells and Their Parental Cell Origins 532 15.4.7 Evolutionary Perspectives of Metabolic Fitness and Selection in Cancer Development 533 15.5 Dual Roles for Metabolism in Both the Generation and Mitigation of Cellular Stress 536 15.5.1 Metabolism and Oxidative Stress 537 15.5.2 Metabolism and Hypoxic Stress 539 15.5.3 Nutritional Stress and Metabolism 539 15.5.4 Metabolism and Physical Stress 540 15.5.5 Metabolism and Other Forms of Cellular Stress 541 15.6 Models of Carcinogenesis 541 15.6.1 Traditional Multistage Models of Cancer Development 542 15.6.2 Role of Replicative Mutagenesis in Cancer Development 543 15.6.3 Acquired Mismatch Model of Carcinogenesis 543 15.7 Potential Metabolic Targets for Environmental Exposures 546 15.7.1 Conceptual Overview of Potential Metabolic Targets 546 15.7.2 Identification of Key Targetable Contributors to Metabolic Dysregulation and Selection 549 15.7.2.1 Glycolysis 555 15.7.2.2 Lipogenesis, Lipolysis, and the PPP 555 15.7.2.3 Citric Acid Cycle 556 15.7.2.4 Organizational or Compartmental Targets 556 15.7.2.5 Metabolite Transport Mechanisms 557 15.7.2.6 Signal Transduction Effectors 558 15.8 Metabolic Changes Associated with Exposures to Selected Agents 559 15.8.1 Selected Agents Classified by the World Health Organization’s International Agency for Research on Cancer (IARC) 559 15.8.1.1 IARC Group 1 (Carcinogenic to Humans) 560 15.8.1.2 IARC Group 2A (Probably Carcinogenic to Humans) 564 15.8.1.3 IARC Group 2B (Possibly Carcinogenic to Humans) 565 15.8.1.4 Other Agents 565 15.8.2 Environmentally Relevant Combinatorial Exposures 567 15.8.2.1 Occupational and Common Environmental Exposures 567 15.8.2.2 Environmentally Relevant Low-Dose Combinatorial Exposures 568 15.8.2.3 The Halifax Project 570 15.9 A Conceptual Overview of Traditional and Emerging Toxicological Approaches to the Problem of Cancer Metabolism: Implications for Future Research 571 15.9.1 General Experimental Considerations in the Study of Metabolism In Vitro 571 15.9.2 Systems Biology and Current Approaches to In Vitro Toxicology Screening 573 15.10 The Nosology of Cancer and Cancer Development 577 15.11 Discussion 579 Acknowledgments 583 References 583 Part Five Biomarkers for Detecting Premalignant Effects and Responses to Protective Therapies during Critical Windows of Development 607 16 Circulating Molecular and Cellular Biomarkers in Cancer 609Ilaria Chiodi, A. Ivana Scovassi, and Chiara Mondello 16.1 Introduction 609 16.2 Proteins in Body Fluids: Potential Biomarkers 610 16.2.1 Diagnostic Protein Biomarkers 612 16.2.2 Prognostic Protein Biomarkers 613 16.2.3 Protein Biomarkers of Drug Response 615 16.3 Circulating Cell-Free Nucleic Acids 615 16.3.1 Circulating Cell-Free Tumor DNA 616 16.3.1.1 Cf-DNA Integrity, Microsatellite Instability, and LOH 617 16.3.1.2 Tumor-Specific Genetic Alterations 617 16.3.1.3 Tumor Genetic Alterations and Therapy Resistance 619 16.3.1.4 Tumor Epigenetic Alterations: DNA Methylation 620 16.3.2 Circulating Cell-Free RNA 621 16.3.2.1 Circulating Cell-Free microRNA 621 16.4 Extracellular Vesicles: General Features 624 16.4.1 Classification of EVs 624 16.4.2 EVs and Cancer 625 16.4.3 EVs as Mediators of Cell-To-Cell Communication 627 16.5 Circulating Tumor Cells 628 16.5.1 Two-Step Processing of Blood Samples: Enrichment and Identification of Circulating Tumor Cells 628 16.5.1.1 CTC Number as a Cancer Biomarker 630 16.5.2 Characterization of CTCs 630 16.5.2.1 Molecular Characterization of CTCs 630 16.5.2.2 Functional Characterization of CTCs 632 16.5.3 Single CTCs versus CTC Clusters 634 16.5.4 In Hiding Before Getting Home, the Long Journey of CTCs 635 16.6 Conclusions 635 References 637 17 Global Profiling Platforms and Data Integration to Inform Systems Biology and Translational Toxicology 657Barbara A. Wetmore 17.1 Introduction 657 17.2 Global Omics Profiling Platforms 659 17.2.1 Genomics 659 17.2.2 Epigenomics 661 17.2.3 Transcriptomics 662 17.2.4 Proteomics 665 17.2.5 Metabolomics 668 17.3 High-Throughput Bioactivity Profiling 669 17.3.1 High-Throughput Bioactivity and Toxicity Screening 669 17.3.2 In Vitro–In Vivo Extrapolation 671 17.4 Biomarkers 672 17.5 Exposomics 673 17.6 Bioinformatics to Support and Data Integration and Multiomics Efforts 674 17.7 Data Integration: Multiomics and High-Dimensional Biology Efforts 676 17.8 Conclusion 679 References 679 18 Developing a Translational Toxicology Therapeutic Portfolio for Cancer Risk Reduction 691Rebecca Johnson and David Kerr 18.1 Introduction 691 18.2 The Identification of Novel Predictors of Adverse Events 693 18.2.1 Candidate Gene Studies 693 18.2.2 Genome-wide Associations 694 18.2.3 Next-Generation Sequencing 695 18.3 Proof of Principle Toxgnostics 696 18.4 Proposed Protocol 698 18.4.1 Integration within Randomized Control Trials 698 18.4.2 Biobanking and Future-Proofing Samples 699 18.4.3 Data Protection and Full Consent 702 18.4.4 The Need for a Collaborative Approach 703 18.4.5 Open Access to Results 704 18.4.6 Translation from Bench to Bedside 705 18.5 Fiscal Matters 706 18.6 The Future of Toxgnostics 706 References 707 19 Ethical Considerations in Developing Strategies for Protecting Fetuses, Neonates, Children, and Adolescents from Exposures to Hazardous Environmental Agents 711David B. Resnik and Melissa J. Mills 19.1 Introduction 711 19.2 What Is Ethics? 712 19.2.1 Some Fundamental Ethical Values 712 19.2.1.1 Benefits and Costs 712 19.2.1.2 Individual Rights and Responsibilities 713 19.2.1.3 Justice 713 19.2.2 Value Conflicts and Ethical Decision-Making 713 19.3 Ethical Considerations for Strategies Used to Protect Fetuses, Neonates, Children, and Adolescents from Exposures to Harmful Environmental Agents 715 19.3.1 Education 715 19.3.2 Testing/Screening/Monitoring 717 19.3.3 Worker Protection 720 19.3.4 Government Regulation 722 19.3.5 Taxation 725 19.3.6 Civil Liability 726 19.3.7 Criminal Liability 729 19.4 Research with Human Participants 730 19.4.1 Return of Individualized Research Results 732 19.4.2 Protecting Privacy and Confidentiality 733 19.4.3 Interventional Studies 734 19.4.4 Intentional Exposure Studies 736 19.4.5 Protecting Vulnerable Participants 739 19.5 Conclusion 742 References 742 Index 751

    1 in stock

    £176.36

  • Textbook of Uncommon Cancer

    John Wiley and Sons Ltd Textbook of Uncommon Cancer

    Out of stock

    Book SynopsisThe fifth edition of the only comprehensive text dealing exclusively with rare or infrequently encountered malignancies in adults and children is an essential resource for any clinical oncologist. Encompasses all the information needed to diagnose and manage uncommon cancers, an area where advice and guidance is typically scarce Fully revised with new material and an evidence-based, teach-by-example approach Provides insight on real-world decision making in the clinical setting Edited and authored by a highly experienced and senior team of medical oncologists, radiation oncologists, and other specialists, giving a balanced and complete overview Extensively illustrated in full color throughout, including heat maps to show gene expression Table of ContentsContributors, xi Preface, xxi Abbreviations, xxiii Section 1 General Principles of Care of Uncommon Cancers 1 A Structured Approach to Uncommon Cancers, 1Derek Raghavan 2 What Patients Need to Know: Information Needs and Information Sources of Patients Diagnosed with Rare Cancers, 6Dana L. Ladd 3 Involving the Public in Rare Cancer Care and Research: Shaping the Future for Rare and Uncommon Cancers, 12Jack S. Nunn, Clare L. Scott, John W. Stubbs, Sarah F. Cherry, and Marie M. Bismark Section 2 Genitourinary Cancers 4 Uncommon Tumors of the Kidney, 19Guillermo De Velasco, Sabina Signoretti, Brian I. Rini, and Toni K. Choueiri 5 Uncommon Cancers of the Bladder, 41Humaid Al‐Shamsi, Donna E. Hansel, Joaquim Bellmunt, and Arlene O. Siefker‐Radtke 6 Urethral Cancer, 54Tanya B. Dorff, Leslie K. Ballas, Anne K. Schuckman,Manju Aron, and David I. Quinn 7 Uncommon Cancers of the Prostate, 68Scott T. Tagawa, Jaspreet S. Batra, Brian D. Robinson, and Ana Aparicio 8 Rare Tumors of the Testis and Paratesticular Tissues, 97Robert Huddart, Anna Patrikidou, and Stephen Hazell 9 Penile Carcinoma, 122J. Ryan Mark, Stephen B. Riggs, David L. Graham,Derek R. McHaffie, Chad A. Livasy, and Earle F. Burgess Section 3 Head and Neck Cancer 10 Uncommon Tumors of the Oral Cavity and Adjacent Structures, 134Madalina Tuluc, Voichita Bar‐Ad, David Cognetti, Jennifer Johnson, and Rita Axelrod 11 Rare Tumors of the Larynx, 152Kenneth J. Niermann, Jill Gilbert, Kyle Mannion, Joseph M. Aulino, Kim Ely, and Barbara A. Murphy 12 Nasopharyngeal Carcinoma in Nonendemic Populations, 165Lachlan McDowell, Annette Lim, and June Corry 13 Esthesioneuroblastoma, 196Christine H. Chung, Gary L. Gallia, Bruce M. Wenig, John A. Arrington, and Jimmy J. Caudell Section 4 Thoracic Tumors 14 Thymoma and Thymic Carcinoma, 214Mohammad Abu Zaid, Kenneth Kesler, Jessica Smith, Sunil Badve, and Patrick J. Loehrer Sr 15 Primary Sarcomas of the Lung, 248Vinod Ravi, Mara Antonoff, Hannah Wingate, Wei‐Lien Wang, and Kelly K. Hunt 16 Mesothelioma, 266Anna K. Nowak, John G. Edwards, and Jenette Creaney 17 Primary Melanoma of the Lung, 285Louise A. Jackett, Richard A. Scolyer, James F. Bishop, and John F. Thompson 18 Large Cell Neuroendocrine Carcinoma, 293Nanna H. Sulai, Edward S. Kim, and Vijayalakshmi Ananthanarayanan 19 Lung Adenocarcinoma: Current Classifications and Uncommon Mutations, 305Kathryn F. Mileham, Jennifer L. Ersek, Edward S. Kim, and Ignacio I. Wistuba 20 Primary Adenoid Cystic Carcinoma of the Lung, 315Charles B. Simone II, John G. Devlin, Sunil Singhal, and Corey J. Langer Section 5 Breast Cancers 21 Metaplastic Breast Cancer, 327Reva K. Basho, Helenice Gobbi, Bryan T. Hennessy, Michael Z. Gilcrease, A. Bapsi Chakravarthy, Gildy Babiera, Wei Yang, Vicente Valero, Gabriel N. Hortobagyi, Stacy L. Moulder, and Ingrid A. Mayer 22 Tubular Carcinoma of the Breast, 338Melinda E. Sanders, Ingrid A. Mayer, and A. Bapsi Chakravarthy 23 Breast Sarcoma, 345Mai‐Kim Gervais, Rebecca A. Gladdy, Abha Gupta, Rita Kandel, and Charles Catton 24 Adenoid Cystic Carcinoma of the Breast, 357Antoinette R. Tan and Chad A. Livasy 25 Breast Cancer in Men, 364Suleiman Alfred Massarweh and George W. Sledge Jr Section 6 Gastrointestinal Tumors 26 Uncommon Tumors of the Esophagus, 377Cristina H. Hajdu, Robert Rosser, and Lawrence Leichman 27 Uncommon Cancers of the Stomach, 395Elizabeta Popa, Felice Schnoll‐Sussman, Arun Jesudian, Govind Nandakumar, and Manish A. Shah 28 Uncommon Cancers of the Small Bowel, 416Kanwal Raghav, Matthew H. G. Katz, and Michael J. Overman 29 Uncommon Cancers of the Pancreas, 429Maria Diab and Philip A. Philip 30 Uncommon Hepatobiliary Tumors, 444Anthony El‐Khoueiry 31 Unusual Tumors of the Colon, Rectum, and Anus, 458Diane Reidy‐Lagunes, Christopher H. Lieu, Wells A. Messersmith, and Karyn Goodman 32 Gastrointestinal Stromal Tumors, 470Margaret von Mehren, Brian P. Rubin, Douglas B. Flieder, and Chandrajit P. Raut Section 7 Gynecological Cancers 33 Surgery for Uncommon Gynecological Cancers, 493R. Wendel Naumann 34 Histologies That Cross Organ Types, 508Amanda Jackson and Preetha Ramalingam 35 Germ Cell Tumors of the Ovary, 518Daniela E. Matei, A. Lindsay Frazier, Jean A. Hurteau, and Farzana D. Pashankar 36 Sex Cord-Stromal Tumors of the Ovary, 533Jubilee Brown, Isabelle Ray‐Coquard, and Kris Ann P. Schultz 37 Clear Cell Carcinoma of the Ovary, 550Keiichi Fujiwara, Katsutoshi Oda, Masashi Takano, and Noriomi Matsumura 38 Mucinous Carcinoma of the Ovary, 557Caroline C. Billingsley and David M. Gershenson 39 Low‐Grade Serous Carcinoma of the Ovary, 564Amanda Nickles Fader and Anais Malpica 40 Borderline Tumors of the Ovary, 572Erin K. Crane and Premal H. Thaker 41 Fallopian Tube and Peritoneal Cancers, 582Destin Black, Kara Long Roche, and Ginger J. Gardner 42 Nonendometrioid Endometrial Carcinomas and Uterine Sarcomas, 591Matthew A. Powell 43 Tumors of the Cervix, 618Krishnansu S. Tewari and Bradley J. Monk 44 Tumors of the Vulva and Vagina, 643Vance Broach and Mario M. Leitao Jr 45 Gestational Trophoblastic Disease, 653John Lurain, Michael Seckl, and Julian Schink 46 Targeted Therapy in Gynecological Malignancy, 663Behrouz Zand, Shannon N. Westin, and Robert L. Coleman Section 8 Endocrine Tumors 47 Adrenal Neoplasms, 681Ashley A. Stewart and Ellen Shannon Story 48 Uncommon Cancers of the Thyroid, 713Bhavana Konda and Manisha H. Shah 49 Parathyroid Carcinoma, 730Colleen Veloski and John A. Ridge Section 9 Hematological Malignancies 50 Rare Acute Leukemias, 740B. Douglas Smith and Jonathan Webster 51 Unusual Myelodysplastic and Myelodysplastic/ Myeloproliferative Neoplasms, 752Eric Padron and Rami Komrokji 52 Rare B Cell Lymphoproliferative Disorders, 760Andrew G. Evans and Paul M. Barr 53 Uncommon Presentations of Plasma Cell Dyscrasias, 776Jason Brayer, Mohamad A. Hussein, and Rachid Baz 54 Rare Bone Marrow Failure Conditions, 793Amy S. Duffield and Amy E. DeZern 55 Myeloproliferative Neoplasms: Chronic Myelogenous Leukemia, Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, 816Raoul Tibes and Ruben A. Mesa 56 Rare T Cell Lymphomas, 830Aleksandr Lazaryan and John Sweetenham Section 10 Neurological Tumors 57 Primary Melanotic Tumors of the Central Nervous System, 840L. Burt Nabors, Rong Li, Cheryl A. Palmer, and Philip R. Chapman 58 Comprehensive Management of Chordoma, 847Varun R. Kshettry, Jennifer S. Yu, Vyshak A. Venur, Manmeet S. Ahluwalia, and Pablo F. Recinos 59 Atypical and Malignant Meningiomas, 856Brandyn A. Castro, Melissa M. J. Chua, and Priscilla K. Brastianos 60 Primary Central Nervous System Lymphoma, 871Macarena I. de la Fuente and Lisa M. DeAngelis 61 Choroid Plexus Tumors, 883Jonathan Aicardi and Nicholas A. Butowski 62 Diffuse Low‐Grade Gliomas, 888Nancy Ann Oberheim Bush, Daniel Yang, Jennifer Clarke, and Daphne Haas‐Kogan 63 High‐Grade Gliomas, 899Ashley L. Sumrall 64 Ependymomas, 907Roberta Rudà, Mark R. Gilbert, and Riccardo Soffietti 65 Medulloblastoma in Adults, 917Anna M. Kenney, Robert C. Castellino, Paul L. Moots, Christopher D. Corso, and Minesh P. Mehta 66 Pineal Parenchymal Tumors, 939Yosuke Kitagawa, Patrick Y. Wen, and Shota Tanaka 67 Craniopharyngiomas, 949Danilo Silva, Mayur Sharma, Gazanfar Rahmathulla, and Gene H. Barnett 68 Ophthalmic Cancers, 964Maria M. Choudhary and Arun D. Singh Section 11 Cutaneous Malignancies 69 Unusual Cutaneous Malignancies, 976Charles T. Darragh, Lee E. Wheless, William G. Stebbins, Jeffrey P. Zwerner, Anthony J. Crimaldi, Thomas Olencki, and Laura Y. McGirt 70 Dermatofibrosarcoma Protuberans, 994Carrie Luu, Jane L. Messina, Andrew S. Brohl, and Vernon K. Sondak 71 Unusual Melanomas, 1002Morganna Freeman, Richard D. Carvajal, Mark Faries, and Omid Hamid Section 12 Musculoskeletal Tumors 72 Uncommon Tumors of Soft Tissue, 1022William Ahrens, Michael Livingston, Robert Lopez, Anthony J. Crimaldi, and Jeffrey Kneisl Section 13 Pediatric Cancers 73 Introduction to Rare Pediatric Malignancies, 1069Alberto S. Pappo and Gregory H. Reaman 74 Uncommon Tumors of the Gastrointestinal Tract in Children, 1072Alberto S. Pappo and Wayne L. Furman 75 Rare Pediatric Malignancies of the Head and Neck, 1088Cynthia E. Herzog, Michael E. Kupferman, Winston Huh, and Anita Mahajan 76 Uncommon Pediatric Tumors of the Thorax, 1097Yoav H. Messinger, Kris Ann P. Schultz, and Louis P. Dehner 77 Uncommon Adrenal Tumors in Children and Adolescents, 1126Raul C. Ribeiro, Carlos Rodriguez‐Galindo, Emilia M. Pinto, Gerard P. Zambetti, and Bonald C. Figueiredo 78 Uncommon Pediatric Genitourinary Tumors, 1138Hans Pohl and Jeffrey S. Dome 79 Uncommon Pediatric Brain Tumors, 1152Robert C. Castellino, Matthew Schniederjan, and Tobey J. MacDonald 80 Malignant Tumors of the Skin and Subcutaneous Tissue in Children, 1172Alberto S. Pappo and Carlos Rodriguez‐Galindo 81 Rare Hematological Malignancies in Children, 1190Abby M. Green and Stephen P. Hunger Index, 1203

    Out of stock

    £298.76

  • Endobronchial Ultrasonography

    John Wiley and Sons Ltd Endobronchial Ultrasonography

    Out of stock

    Book SynopsisEndobronchial ultrasonography (EBUS) is an exciting and still developing diagnostic tool that has added significantly to the diagnosis and staging of lung cancer and other thoracic diseases. Co-authored by one of the technology''s pioneers, this bookhelps the reader to use EBUS to diagnose and stage lung cancer and a variety of different tumours of the chest region. The second edition of Endobronchial Ultrasonography covers all of the standard techniques and the very latest developments and guidelines involved in EBUS, combining two common procedures, bronchoscopy and real-timeultrasonography, allowing physicians to obtain precise biopsies of lymph nodes and masses within the chest cavity.Table of ContentsForeword vii About the Companion Website ix 1 Endobronchial Ultrasonography: An Overview 1Noriaki Kurimoto 2 Identifying Peribronchial Organs during Endobronchial Ultrasonography 19Noriaki Kurimoto 3 How to Perform Endobronchial Ultrasonography 31Noriaki Kurimoto 4 Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration 43Christopher Kniese and Ali I. Musani 5 Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: Tips and Tricks 63David I.K. Fielding 6 Endoscopic Ultrasound-Guided Mediastinal Lymph Node Aspiration for Lung Cancer Diagnosis and Staging 81Christopher Kniese and Ali I. Musani 7 How to Accurately Identify the Bronchial Pathway to a Peripheral Pulmonary Lesion 87Noriaki Kurimoto 8 Qualitative Analysis of Peripheral Pulmonary Lesions Using Endobronchial Ultrasonography 103Noriaki Kurimoto 9 Diagnosis of Peripheral Pulmonary Lesions Using Endobronchial Ultrasonography with a Guide Sheath 115Noriaki Kurimoto 10 Endobronchial Ultrasonography with a Guide Sheath: Up to Date 125David I.K. Fielding 11 Endobronchial Ultrasonography for Ground‐Glass Opacity Lesions 133David I.K. Fielding 12 Techniques for Comparing Endobronchial Ultrasonography Images of Peripheral Pulmonary Lesions with Macroscopy and Histopathology Findings 137Katsuhiko Morita 13 Endobronchial Ultrasonography of Airway Integrity and Tumor Involvement 157David I.K. Fielding 14 Endobronchial Ultrasonography in Interventional Bronchoscopy 167Christopher Kniese and Ali I. Musani 15 Cytopathology in Endobronchial Ultrasound‐Guided Transbronchial Needle Aspiration of Mediastinal and Hilar Lymph Nodes 177Christopher Kniese and Ali I. Musani 16 Future Directions for Endobronchial Ultrasonography 187David I.K. Fielding Appendix: Videos 193 Index 219

    Out of stock

    £116.06

  • John Wiley and Sons Ltd TNM Classification of Malignant Tumours

    Out of stock

    Book SynopsisTNM Classification of Malignant Tumours eighth edition provides the latest, internationally agreed-upon standards to describe and categorize cancer stage.Table of ContentsPreface XII Acknowledgments XIV Organizations Associated with the TNM System XV Members of UICC Committees Associated with the TNM System XVI Section Editors XVII Introduction 1 Head and Neck Tumours 17 Lip and Oral Cavity 18 Pharynx 22 Larynx 31 Nasal Cavity and Paranasal Sinuses 36 Unknown Primary – Cervical Nodes 40 Malignant Melanoma of Upper Aerodigestive Tract 45 Major Salivary Glands 47 Thyroid Gland 51 Digestive System Tumours 55 Oesophagus and Oesophagogastric Junction 57 Stomach 63 Small Intestine 67 Appendix 70 Colon and Rectum 73 Anal Canal and Perianal Skin 77 Liver 80 Intrahepatic Bile Ducts 83 Gallbladder 85 Perihilar Bile Ducts 87 Distal Extrahepatic Bile Duct 89 Ampulla of Vater 91 Pancreas 93 Well‐Differentiated Neuroendocrine Tumours of the Gastrointestinal Tract 96 Lung, Pleural, and Thymic Tumours 105 Lung 106 Pleural Mesothelioma 113 Thymic Tumours 115 Tumours of Bone and Soft Tissues 119 Bone 120 Soft Tissues 124 Gastrointestinal Stromal Tumour (GIST) 127 Skin Tumours 131 Carcinoma of Skin 133 Skin Carcinoma of the Head and Neck 136 Carcinoma of Skin of the Eyelid 139 Malignant Melanoma of Skin 142 Merkel Cell Carcinoma of Skin 147 Breast Tumours 151 Gynaecological Tumours 159 Vulva 161 Vagina 164 Cervix Uteri 166 Uterus – Endometrium 171 Uterine Sarcomas 175 Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma 179 Gestational Trophoblastic Neoplasms 184 Urological Tumours 187 Penis 188 Prostate 191 Testis 195 Kidney 199 Renal Pelvis and Ureter 202 Urinary Bladder 204 Urethra 208 Adrenal Cortex 211 Ophthalmic Tumours 215 Carcinoma of Conjunctiva 216 Malignant Melanoma of Conjunctiva 218 Malignant Melanoma of Uvea 221 Retinoblastoma 226 Sarcoma of Orbit 230 Carcinoma of Lacrimal Gland 232 Hodgkin Lymphoma 235 Non‐Hodgkin Lymphomas 239 Essential TNM 241 Paediatric Tumours 247 Gastrointestinal Tumours 247 Bone and Soft Tissue Tumours 248 Gynaecological Tumours 249 Urological Tumours 250 Ophthalmic Tumours 251 Malignant Lymphoma 252 Central Nervous System 252

    Out of stock

    £36.05

  • Atlas of Dermatopathology

    John Wiley and Sons Ltd Atlas of Dermatopathology

    Out of stock

    Book SynopsisDifferential diagnosis is at its most accurate and efficient when clinical presentation and histopathological features are considered in correlation with one another. With this being so, the expert team behind this atlas has integrated both perspectives to create an innovative and essential resource for all those involved with the diagnosis of tumors, cysts, and nevi. Almost 1,400 full-color images clearly illustrate common patterns and variants of tumorous lesions of the skin and are helpfully contextualized by concise, straightforward descriptions of key features and diagnostic clues. Whether they are aspiring or experienced practitioners, dermatologists and pathologistsof all levels will find this an insightful and practically applicable addition to their bookshelf. Its far-reaching and easy-to-navigate coverage of relevant diseases of the skin provides trainees with an excellent grounding in the area, while practicing specialists may benefit from its use as a tool for theTable of ContentsPreface xv Acknowledgments xvii 1 EPIDERMIS 1 Nevi 2 Epidermal Nevus 2 Variant: Inflammatory Linear Verrucous Epidermal Nevus (ILVEN) 3 Keratoses 4 Seborrheic Keratosis (SK) and Variants 4 Variant: Acanthotic Seborrheic Keratosis 4 Variant: Reticulated, Pigmented Seborrheic Keratosis 6 Variant: Flat Seborrheic Keratosis 6 Variant: Papillomatous Seborrheic Keratosis 7 Variant: Activated (Irritated) Seborrheic Keratosis 7 Variant: Dermatosis Papulosa Nigra 7 Variant: Melanoacanthoma (Pigmented Seborrheic Keratosis) 8 Variant: Clonal (Intraepidermal) Seborrheic Keratosis (Borst– Jadassohn) 9 Variant: Seborrheic Keratosis with Monster Cells (Bowenoid) 10 Variant: Hyperkeratotic Seborrheic Keratosis (Stucco Keratosis) 11 Confluent and Reticulate Papillomatosis (Gougerot and Carteaud) 12 Reticulate Pigmented Anomaly of the Flexures (Dowling–Degos Disease) 13 Acanthosis Nigricans 14 Solar (Actinic) Keratosis 15 Variant: Acantholytic Solar Keratosis 16 Variant: Atrophic Solar Keratosis 16 Variant: Lichen Planus‐Like Solar Keratosis 17 Variant: Hypertrophic (Bowenoid) Solar Keratosis 18 Cornu Cutaneum 18 Acanthomas, Non‐Viral 19 Solar Lentigo 19 Callus, Factitial Acanthoma 20 Knuckle Pads (Chewing Pads) 21 Pale (Clear) Cell Acanthoma 22 Large Cell Acanthoma 23 Differential Diagnosis: Epidermolytic Acanthoma 24 Differential Diagnosis: Congenital Ichthyosiform Erythroderma 25 Acantholytic Acanthoma 26 Warty Dyskeratoma 27 Porokeratoma (Porokeratosis Mibelli) 30 Acanthomas, Viral 31 Verruca Vulgaris 31 Variant: Verruca Plana 33 Variant: Condyloma Acuminatum 34 Bowenoid Papulosis 35 Acrokeratosis Verruciformis (Hopf) 37 Molluscum Contagiosum 38 “Pseudocarcinomas” and Neoplasms with Intermediate Malignant Potential 40 Keratoacanthoma (KA) 40 Epithelioma Cuniculatum (Verrucous Carcinoma) (EC/VC) 44 Papillomatosis Cutis Carcinoides 45 Florid Papillomatosis of the Oral Cavity (Oral Verrucous Carcinoma) 46 Buschke–Löwenstein Tumor (Giant Condyloma) 47 Malignant Epidermal Neoplasms 48 Bowen’s Disease (Carcinoma in situ) 48 Variant: Clear Cell Bowen’s Disease 50 Variant: Cutaneous Horn (Cornu Cutaneum) on Bowen’s Disease 51 Variant: Pigmented (Anogenital) and Clonal Bowen’s Disease 52 Variant: Erythroplasia of Queyrat and Vulvar Intraepithelial Neoplasia 53 Basal Cell Carcinoma (BCC) 54 Variant: Nodular BCC 54 Variant: Infundibulocystic BCC 56 Variants of BCC With Ductal, Matrical or Sebaceous Differentiation 57 Variant: Superficial BCC 60 Variant: Pigmented BCC 61 Variant: Adenoid‐Cystic BCC 62 Variant: Sclerodermiform (Morpheaform) BCC 64 Clinical Variants: Ulcerating BCCs 66 Histological Variants: Metatypic BCC with Squamoid Differentiation 67 Syndromatic BCC (Basal Cell Nevus Syndrome, Gorlin–Goltz) 69 Fibroepithelioma of Pinkus 70 Squamous Cell Carcinoma (SCC) 72 Variant: Well‐Differentiated SCC 72 Variant: Acantholytic SCC (Epithelioma Spinocellulare Segregans of Delacretaz) 74 Variant: Myxoid SCC 76 Variant: Follicular (Infundibular) SCC 77 Variant: Spindle Cell (Fusicellular) SCC 78 Squamous Cell Carcinomas in Special Sites 79 2 ADNEXAL 85 Sweat Gland Differentiation 86 Nevi, Hyperplasias, and Benign Adnexal Neoplasms (BAN) 86 Eccrine Differentiation 86 Apocrine Differentiation 93 Malignant Adnexal Neoplasms 105 Eccrine Differentiation 105 Apocrine Differentiation 109 Sebaceous Differentiation 110 Hyperplasias and Hamartomas 111 Ectopic (Heterotopic) Sebaceous Glands (Fordyce Glands) 111 (Senile) Sebaceous Gland Hyperplasia 112 Nevus Sebaceous (Jadassohn) 113 Variant: Pilo‐Sebaceous Hamartoma 114 Benign Neoplasms 114 Sebaceous Adenoma 114 Muir–Torre Syndrome 115 Sebaceous Epithelioma (Sebaceoma) 116 Malignant Neoplasms 118 Sebaceous Carcinoma 118 Hair Follicle Differentiation 119 Nevi, Hyperplasia, and Hamartomas 119 Hair Follicle Nevus 119 Conical Infundibular Acanthoma (Giant Dilated Pore of Winer) 120 Benign Neoplasms 121 Pilar Sheath Acanthoma 121 Trichilemmoma (Tricholemmoma) 122 Tumor of the Follicular Infundibulum (Infundibuloma) 124 Trichoepithelioma (Superficial Trichoblastoma) 125 Trichoblastoma (Trichoblastic Fibroma; Immature Trichoepithelioma) 127 Trichoepithelioma (Sclerosing Epithelial Hamartoma) 131 Trichofolliculoma (Folliculosebaceous Cystic Hamartoma) 133 Trichoadenoma (Nikolowski) 136 Pilomatricoma (Calcifying Epithelioma Malherbe) 137 Proliferating Trichilemmal (Pilar) Tumor (PTT) (Proliferating Trichilemmal Cyst) 138 Malignant Neoplasms 140 Malignant Pilomatricoma (Pilomatrical Carcinoma) 140 Trichilemmal Carcinoma 141 Trichoblastic Carcinoma 142 Pilosebaceous Mesenchyme 143 Benign Neoplasm 143 Trichodiscoma (Follicular Fibroma, Fibrofolliculoma, Perifollicular Fibroma) 143 3 PAGET’S DISEASE 145 Mammary Paget’s Disease 146 Extramammary Paget’s Disease 146 4 MELANOCYTES 149 Non‐Neoplastic Hyperpigmentations 150 Ephelides (Genuine Freckles) 150 PUVA (Psoralen UVA) Lentigo 150 “Nevus” Spilus (Speckled Lentiginous Nevus; Café‐Au‐Lait Spot) 151 “Ink” Spot Lentigo (Reticulated Melanocytic Macule) 152 Senile Freckles (Solar [Actinic] Lentigo) 153 Mucosal Lentiginous Spots (Lip, Buccal, and Genital Mucosa) 154 Nevi 155 Common Acquired Melanocytic Nevi 155 Melanosis Neviformis (Pigmented Hairy Epidermal Nevus; Becker Nevus) 155 Junctional Nevus 156 Compound Nevus 157 Dermal Nevus 158 Variant: Miescher’s Nevus (Dermal Nevus) 160 Variant: Balloon Cell Nevus 161 Variant: “Activated” Acral (Lentiginous) Melanocytic Nevus 161 Variant: (Atypical) Genital Melanocytic Nevus 162 Variant: Halo Nevus (Leukoderma Centrifugum Acquisitum; Sutton Nevus) 163 Variant: Eczematoid Melanocytic (Meyerson’s) Nevus 165 Variant: Osteo‐Nevus of Nanta 166 Variant: Combined Epithelioid Spitzoid Nevus, “Wiesner Nevus” (BAP-1 Deficient Epithelioid Melanocytic Tumor) 167 Variant: Recurrent (Persistent) Melanocytic Nevus (Pseudomelanoma) 167 Variant: Nevus in Pregnancy 168 Variant: Ancient Nevus 170 Blue Nevi 171 Common Blue Nevus 171 Common Blue Nevus 172 Dermal Melanocytosis 177 Nevus Fuscoceruleus (Ota; Ito; Mongolian Spot) 177 Spindle and/or Epithelioid Cell Nevus 178 Common Nevus of Spitz 178 Variants of Spindle and Epithelioid Cell Nevus 179 Variant: Pigmented Spindle Cell Nevus (Reed) 182 Benign Melanocytic Lesions with Peculiar Structural Features 183 Melanocytic Nevus with Clonal Proliferation 183 Atypical (Dysplastic) Melanocytic (Clark’s) Nevus (B‐K Mole Syndrome) 185 Congenital Nevi, Small and Medium‐Sized (1.5–20 cm) 186 Malignant Melanocytic Neoplasms 188 Lentigo Maligna Dubreuilh (Hutchinson’s Freckle) 188 Malignant Melanoma 189 Variant: Superficial Spreading Melanoma (SSM) 190 Variant: Lentigo Maligna Melanoma (LMM) 192 Variant: Nodular Melanoma (NM) 193 Variant: Acral Lentiginous Melanoma (ALM) 194 Variant: Melanoma in Large Congenital Melanocytic Nevus (LCMN) 196 Variant: Cutaneous Metastasis of Melanoma 197 Special Localisations of Malignant Melanoma 204 Tumor Thickness and Levels 205 Common Clinical Differential Diagnoses of Malignant Melanoma 205 5 CONNECTIVE TISSUE 207 Nevi 208 Connective Tissue Nevus (Shagreen Patch; Cobblestone Nevus; Nevus Collagenicus) 208 Fibrous Neoplasms 209 Soft Fibroma (Skin Tag; Acrochordon) 209 Perifollicular Fibroma (Fibrofolliculoma; Trichodiscoma) 210 Variant: Sclerotic Fibroma (Plywood Fibroma; Storiform Collagenoma) 211 Variant: Fibrous Papule of the Nose 212 Variant: Pleomorphic Sclerosing Fibroma with Multinucleated Cells 212 Keloid 213 Infantile Digital Fibromatosis (Inclusion Body Fibromatosis; Recurring Digital Fibrous Tumor of Children; Reye’s Tumor) 214 Malformations with Supernumerary Tissue Elements 216 Supernumerary Digit (Rudimentary Digit; Rudimentary Polydactyly) 216 Differential Diagnosis: Acral Acquired Fibrokeratoma 216 Accessory Tragus (Preauricular Tag) 217 Accessory Nipple (Ectopic Breast; Polythelia) 218 Fibrohistiocytic Neoplasms 218 Dermatofibroma (Benign Fibrous Histiocytoma; Fibroma Durum; Sclerosing Hemangioma) 218 Dermatofibrosarcoma Protuberans 227 Variant: Pigmented Dermatofibrosarcoma Protuberans (Bednar’s Tumor) 230 Variant: Giant Cell Fibroblastoma 231 Pleomorphic Dermal Sarcoma (PDS) 231 Miscellaneous Tumors 234 Epithelioid Sarcoma 234 Dermatomyofibroma 236 6 VESSELS 239 Hamartomas, Nevi, and Malformations 240 Phacomatosis Pigmentovascularis 240 Eccrine Angiomatous Hamartoma 241 Nevus Anemicus 242 Capillary Malformations 242 Nevus Flammeus (Port-Wine Stain) 242 Nevus Araneus (Spider Angioma) 244 Cutis Marmorata Telangiectatica (van Lohuizen) (Nevus Vascularis Reticularis) 245 Congenital Telangiectatic Erythema (Bloom’s Syndrome) 247 Venous Malformations 248 Blue Rubber Bleb Nevus Syndrome (Familial Venous Malformation) 248 Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu) 249 Angioma Serpiginosum 250 Venular Aneurysm (Venous Lake) 251 Cavernous Hemangioma (in Maffucci Syndrome) 252 Sinusoidal Hemangioma 253 Spindle Cell Hemangioma (Formerly Spindle Cell Hemangioendothelioma) 254 Arteriovenous Malformations 256 Acral Arteriovenous Hemangioma (Cirsoid Aneurysm) 256 Glomuvenular Malformation (“Glomangioma”) 257 Lymphatic Malformations 259 Superficial Lymphatic Malformation (Superficial Lymphangioma) 259 Cystic Lymphatic Malformation (Cystic Hygroma) 260 Targetoid Hemosiderotic (Hobnail) Hemangioma 261 Progressive Lymphangioma (Benign Lymphangioendothelioma) 262 Lymphangiomatosis 263 Angiokeratomas 264 Verrucous Hemangioma (Venous Malformation) 265 Variant: Solitary Angiokeratoma 268 Variant: Angiokeratoma Circumscriptum Naeviformis 269 Variant: Fordyce Angiokeratoma 269 Variant: Angiokeratoma Acroasphycticum Digitorum (Mibelli) 269 Variant: Multiple “Pinpoint” Angiokeratomas (Angiokeratoma Corporis Diffusum; Fabry’s Disease) 269 Variant: Acral Pseudolymphomatous Angiokeratoma of Children (APACHE) 269 Hyperplasias 270 Granuloma Pyogenicum (Lobular Capillary Hemangioma; Botryomykoma) 270 Differential Diagnosis: Pyogenic Granuloma‐Like Granulation Tissue 272 Bacillary Angiomatosis 273 Verruga Peruana 274 Intravascular Papillary Endothelial Hyperplasia (Masson) 275 Acroangiodermatitis Mali (Pseudo‑Kaposi’s Sarcoma) 276 Benign Vascular Neoplasms 278 Epithelioid Hemangioma (Angiolymphoid Hyperplasia with Eosinophilia, ALHE) 278 Endothelial Differentiation 280 Infantile Capillary and Congenital Hemangioma 280 Cherry Angioma (Senile Hemangioma) 281 Microvenular (Microcapillary) Hemangioma 282 Tufted Angioma 283 Kaposiform Hemangioendothelioma 285 Glomeruloid Hemangioma in POEMS Syndrome 287 Pericytic Differentiation 288 Imitator: Solitary Fibrous Tumor of the Skin (SFT) 289 Myopericytoma (Infantile Myofibromatosis; Perivascular Myoma (incl. Myofibroma)) 290 Glomoid and Myoid Differentiation 292 Glomus Tumor 292 Angioleiomyoma (Angiomyoma; Vascular Leiomyoma) 294 Recently Described Benign Vascular Tumors 296 Symplastic Hemangioma 296 Papillary Hemangioma 297 Vascular Neoplasms of Intermediate Malignant Potential 298 Kaposi’s Sarcoma (KS) 298 Retiform Hemangioendothelioma 305 Composite Hemangioendothelioma 306 Papillary Intralymphatic Angioendothelioma (PILA) (Malignant Endovascular Papillary Angioendothelioma (Dabska Tumor); Endovascular Papillary Hemangioendothelioma) 306 Radiation‐Induced Atypical Vascular Lesion (AVL) (Benign Lymphangiomatous Papule (BLAP)) 308 Vascular Neoplasms with High Malignant Potential 309 Cutaneous Angiosarcoma 309 Radiation‐Induced (Postradiation) Angiosarcoma 312 Epithelioid Hemangioendothelioma 312 Epithelioid Angiosarcoma 315 Differential Diagnosis: Acantholytic (Angiosarcoma‐Like) Squamous Cell Carcinoma 316 Glomangiosarcoma (Malignant Glomus Tumor) 317 Other Neoplasms with Significant Vascular Component 318 Multinucleate Angiohistiocytoma 318 Angiofibroma (Adenoma Sebaceum Associated with Pringle–Bourneville Disease) 319 Angiolipoma 321 Angiolipoleiomyoma (Angiomyolipoma) 322 Angiomyxoma 322 Intralymphatic Histiocytosis 324 Kimura’s Disease 325 7 FAT 327 Nevus (Hamartoma) 328 Nevus Lipomatosus Superficialis Hoffmann Zurhelle 328 Neoplasms of Fat Tissue 329 Benign Neoplasms 329 Common Lipoma and Lipomatosis 329 Angiolipoma (see Vessels, Chapter 6) 330 Angiomyolipoma (see Vessels, Chapter 6) 330 Spindle Cell Lipoma 330 Pleomorphic Lipoma (see Pleomorphic Liposarcoma) 332 Hibernoma 332 Malignant Neoplasms 333 Cutaneous Liposarcoma 333 8 MUSCLE 337 Benign Neoplasms 338 Piloleiomyoma (Pilar Leiomyoma) 338 Angioleiomyoma (see Vessels, Chapter 6) 340 Rhabdomyoma, Adult Type 340 Malignant Neoplasms 341 Rhabdomyosarcoma 341 Superficial Leiomyosarcoma 342 9 NERVES 345 Benign Neoplasms 346 Schwannoma (Neurilemmoma) 349 Solitary Neuroma (“Palisaded Encapsulated Neuroma”) 352 Variant: Traumatic Neuroma 353 Granular Cell Tumor (Abrikossoff) 354 Dermal Nerve Sheath Myxoma (Myxoid Neurothekeoma) 356 Variant: Cellular Neurothekeoma 357 Pacinian Neurofibroma (Pacinoma) 358 Malignant Neoplasms 358 Malignant Peripheral Nerve Sheath Tumor (Malignant Schwannoma) 358 Malignant Granular Cell Tumor 360 Neuroendocrine Neoplasm 360 Primary Neuroendocrine (Merkel Cell, Trabecular) Carcinoma of the Skin 360 10 MAST CELLS 363 Solitary Cutaneous Mast Cell Proliferation 364 Cutaneous Mastocytoma 364 Diffuse Cutaneous Mast Cell Proliferations 365 Urticaria Pigmentosa (Juvenile Maculopapular Mastocytosis) 365 Telangiectasia Macularis Eruptiva Perstans (Adults) 365 Systemic Mast Cell Proliferation 367 Involvement of Skin and Bone Marrow 367 11 HISTIOCYTES 369 Langerhans Cell Histiocytoses (LCH) 370 Precursors of Langerhans Cell Histiocytoses 370 Congenital Self‐healing Reticulohistiocytosis (Hashimoto–Pritzker) 370 Indeterminate Cell Histiocytosis 371 Langerhans Cell Histiocytoses (Histiocytosis X) 371 Congenital Langerhans Cell Histiocytosis (Letterer–Siwe Disease) 372 Hand–Schüller–Christian Adult LHC Histiocytosis 374 Solitary Langerhans Cell Tumor (Eosinophilic Granuloma) 375 Non‐Langerhans Cell Histiocytoses 376 Proliferative 376 Proliferative Histiocytoma (Progressive Nodular Histiocytosis, PNH) 376 Benign Cephalic Histiocytosis 377 Multicentric Reticulohistiocytosis (Lipoid Dermatoarthritis) (Solitary Reticulohistiocytoma) 378 Sinus Histiocytosis With Massive Lymphadenopathy 379 Granulomatous Storing 380 Juvenile Xanthogranuloma (Nevoxanthoendothelioma; Xanthoma Multiplex; Juvenile Giant Cell Granuloma) 380 Xanthelasma Palpebrarum 383 Verruciform Xanthoma 384 Necrobiotic Xanthogranuloma (with Paraproteinemia) 385 Hereditary Progressive Mucinous Histiocytosis 386 Hemophagocytic 387 Familial Hemophagocytic Lymphohistiocytosis 387 Histiocytic Cytophagic Panniculitis 388 12 HEMATOPOIETIC DISORDERS 389 Lymphoid Skin Infiltrates 389 Cytomorphology, Major Cell Types 390 T‐Cells 390 B‐Cells 391 Pattern of Small Cell Lymphocytic Infiltrates 392 T‐Cell Pattern 392 B‐Cell Pattern 392 Pseudolymphoma (PL) 393 Nodular B‐Cell PL 393 Lymphadenosis Cutis Benigna (Lymphocytoma Cutis) 393 Differentiation between B‑Pseudolymphoma (PL) and Cutaneous B‐Cell Lymphoma (CBCL) 395 Nodular T‐Cell PL 396 CD30+ Pseudolymphoma in Scabies 396 Papular (Secondary) Syphilis 398 Pseudo‐Mycosis Fungoides (Mycosis Fungoides Simulators) 399 Lymphomatoid Contact Dermatitis 399 Lichen Planus 399 Drug Reactions 400 Early Vitiligo 400 Lichen Sclerosus et Atrophicus 400 Pityriasis Lichenoides Chronica 401 Graft Versus Host Reaction (Acute) 401 Pityriasis Lichenoides et Varioliformis Acuta (PLEVA) 402 Pigmented Purpuric Dermatitis (Lichen Aureus) 403 Lymphocytic Infiltration Jessner–Kanof 404 Cutaneous Mature T‐Cell Lymphoid Neoplasms (CTCL) 405 Mycosis Fungoides, Classic Alibert–Bazin Type 405 Mycosis Fungoides Patch Stage I 405 Mycosis Fungoides Plaque Stage II (CD4+; CD8−) 407 Variant: CD8+ Mycosis Fungoides 409 Mycosis Fungoides Tumor Stage III 409 Large Cell Transformation 410 Simulators and Variants of Mycosis Fungoides: “Parapsoriasis” 411 Simulator: Small Plaque Parapsoriasis (SPP) (Brocq’s Disease, Digitate Dermatosis) 411 Large Plaque Parapsoriasis (LPP) 412 Pigmented Purpuric Mycosis Fungoides 412 Erythrodermic Mycosis Fungoides 412 Folliculotropic (Pilotropic) Mycosis Fungoides 413 Syringotropic Mycosis Fungoides (Syringolymphoid Hyperplasia with Alopecia) 414 Granulomatous Mycosis Fungoides 415 Granulomatous Slack Skin 415 Pagetoid Reticulosis (PR), Unilesional (Woringer–Kolopp) 417 Sézary Syndrome (SS) 418 Variant: Sézary Syndrome, Large Cell Transformation 420 CD30‐Positive Lymphoproliferative Disorders (LPD) of the Skin 423 Anaplastic Large Cell Lymphoma (ALCL) 424 Neutrophil‐Rich (Pyogenic) Anaplastic Large Cell Lymphoma 426 Lymphomatoid Papulosis 427 Differential Diagnosis: Hodgkin’s Lymphoma, Lymphocyte Predominance 429 Subcutaneous Panniculitis‐Like Lymphoma 431 Subcutaneous (Panniculitis-Like; Alpha/Beta) T‐Cell Lymphoma 431 Differential Diagnosis: Subcutaneous (Panniculitis‐Like) Gamma/Delta lymphoma 432 Differential Diagnosis: Lupus Panniculitis (Lupus Profundus) 433 Primary Cutaneous Peripheral Lymphoma (PTL), Unspecified (NOS) 434 Primary Cutaneous CD4‐positive (Acral) Small/Medium‐Sized T‐Cell Lymphoproliferative Disorder 435 Cutaneous Aggressive Epidermotropic CD8‐positive T‐Cell Lymphoma (Berti) 436 Differential Diagnosis: Febrile Ulceronecrotic PLEVA (Mucha–Habermann Disease) 437 Extranodal NK/T‐Cell Lymphoma, Nasal Type (Subcutaneous) 439 Hydroa Vacciniforme‐Like Lymphoma 440 Angioimmunoblastic T‐Cell Lymphoma 441 Cutaneous Mature B‐Cell Lymphoid Neoplasms (CBCL) 443 Cutaneous Marginal Zone B‐Cell Lymphoma (MZL; MALT Type) 444 Variant: Immunocytoma 447 Differential Diagnoses: Multiple Myeloma/Plasmacytoma 448 Primary Cutaneous Follicle Center Lymphoma (FCL) 449 Diffuse Large B‐Cell Lymphoma (DLBCL) 451 Variant: Cutaneous Diffuse Large B‐Cell Lymphoma (Leg Type) 451 Variant: T‐Cell‐Rich B‐Cell Lymphoma (DLBCL) 454 Cutaneous Spindle B‐Cell Lymphoma 455 Extracutaneous B‐Cell Lymphoma (BCL) with Frequent Skin Involvement 457 Mantle Cell Lymphoma 457 Burkitt’s Lymphoma (BL) 458 Lymphomatoid Granulomatosis (Liebow) (LYG) 460 Intravascular Lymphomas 461 Intravascular Large B‐Cell Lymphoma (IV‐LBCL) (Systemic Angioendotheliomatosis) 461 Intravascular T Cell Lymphoma 462 Secondary Skin Involvement in Leukemias/Lymphomas 463 Chronic Lymphocytic Leukemia (CLL) 463 Myeloid and Monocytic Leukemias 464 T‐Zone Lymphoma 466 Adult T‐Cell Leukemia/ Lymphoma (ATLL) 467 Immature Hematopoietic Malignancies 468 Blastic Plasmacytoid Dendritic Cell Neoplasm 468 Precursor Lymphoblastic Leukemia/Lymphoma 470 13 CUTANEOUS CYSTS 471 Cysts with Epithelial Lining 472 Stratified Squamous Epithelium 472 Epidermal (Infundibular) Cysts 472 Variant: Epidermal Proliferating Cyst 473 Variant: Epidermal Cyst with Pigment and Vellus Hairs 473 Vellus Hair Cyst 474 Trichilemmal (Isthmus‐Catagen) Cyst 475 Milia 476 Follicular Hybrid Cyst 477 Hidrocystoma (Cystadenoma) 478 Steatocystoma, Multiplex and Simplex 481 Dermoid Cyst 482 Pilonidal Sinus (Pilonidal Cyst) 484 Non‐Stratified Squamous Epithelium 485 Cutaneous Ciliated Cyst of the Lower Limb 485 Median Raphe Cyst 486 Cysts without Epithelial Lining (Pseudocysts) 487 Oral Mucous Cyst and Superficial Mucocele of the Lip 487 Digital Myxoid Cyst 488 Synovial Cyst (Ganglion) 490 Index 491

    Out of stock

    £117.75

  • The Application of Heat in Oncology

    John Wiley & Sons Inc The Application of Heat in Oncology

    5 in stock

    Book SynopsisTHE APPLICATION OF HEAT IN ONCOLOGY Understand the use of heat to destroy tumors with this comprehensive guide Heat is an indispensable resource in the destruction of cancerous tumors to potentially treat cancers. There are also real challenges, however, involved in the total destruction of tumors without destroying healthy tissue surrounding the tumor in the process. A detailed understanding of the propagation of thermal energy, induced heating, and tissue responses to heat is required to safely and successfully apply heat-based technologies in clinical oncology. The Application of Heat in Oncology supplies this understanding, with a thorough, comprehensive overview of the principle and practice involved. Offering both a detailed introduction to the physics and thermodynamics of induced heat and an analysis of its clinical applications, this is an essential resource for clinicians, technicians, and others in oncological practice. The Application of Heat in Oncology readers will also find: Guidelines for applying heat both safely and effectivelyDetailed discussion of topics including energy delivery (e.g., via RF, MW, ultrasound, laser, cryoagents, hyperthermia, nanoparticles, etc.), temperature assessment, damage assessment, image guidance, and moreSummary of current practice along with suggestions for future areas of technological improvement The Application of Heat in Oncology is ideal for all clinicians working in the field of cancer treatment, including medical students, residents, researchers, engineers, radiologists, surgeons, and more.Table of ContentsList of Contributors xxi Preface xxv Part A Principles 1 A.1 Delivering Energy 3 1 Propagation of Radiofrequency and Microwaves in Tissue 5Punit Prakash and Anna Bottiglieri 2 Propagation of Focused Ultrasound in Tissue 19Gregory T. Clement 3 Propagation of Light in Tissue 31Do-Hyun Kim 4 Mechanisms of Tissue Injury in Cryosurgery 45John G. Baust, Kimberly L. Santucci, Kristi K. Snyder, Anthony Robilotto, and John M. Baust 5 Delivering Energy using Localized Hyperthermia Systems 73Hana Dobsicek Trefna, Johannes Crezee, and Petra Kok 6 Role of Nanoparticles Mediated Heating in Oncology 95Gennaro Bellizzi A.2 Assessing Temperatures 107 7 Temperature Monitoring During Thermal Treatment by Thermocouples and Thermistors: Current Status and Perspectives 109Francesca De Tommasi, Carlo Massaroni, Daniela Lo Presti, Rosario Francesco Grasso, Massimiliano Carassiti, Yuman Fong, and Emiliano Schena 8 Fluorescent-Decay Temperature Probes for Biomedical Applications: Theory, Techniques, and Practical Advice 121Daryl James and Harry Vine 9 Calibration and Use of Infrared Thermal Cameras in Biological Applications 135Michael L. Denton and Gary D. Noojin 10 Magnetic Resonance Thermometry in Oncology: Applications in Moving Organs 149Henrik Odéen and Dennis L. Parker 11 Measuring Tissue Temperature with Ultrasound 175Elyas Shaswary and Jahangir (Jahan) Tavakkoli 12 Current Status and Future Potential of Thermometry Based on Computed Tomography Imaging 195Francesca De Tommasi, Carlo Massaroni, Daniela Lo Presti, Rosario Francesco Grasso, Massimiliano Carassiti, Yuman Fong, and Emiliano Schena 13 A Generic Thermal Model to Predict Temperatures in Perfused Tissues 205Devashish Shrivastava A.3 Assessing Damage 217 14 Measuring Thermal Damage with Gross and Microscopic Pathology 219Sharon Thomsen 15 Assessing Thermal Damage with Magnetic Resonance Imaging 251Sara L. Johnson and Allison H. Payne 16 Ultrasound Imaging Techniques for the Evaluation of Thermal Damage 273Jenna Osborn 17 Mathematical Models of Thermal Damage and Cell Death 289John Pearce 18 A Novel Method to Indicate Onset of Photothermal Damage 307Michael L. Denton, Gary D. Noojin, and Elharith M. Ahmed 19 Thermodynamic Challenges of Using Magnetic Resonance Thermometry in Measuring in vivo Temperatures and Estimating Thermal Damage in Thermal Ablation 329Devashish Shrivastava Part B Clinical Applications 341 20 Biological and Physical Aspects of Heat Therapy 343Abhijit Mandal, Ritusha Mishra, and Himanshu Mishra 21 Guiding Thermal Therapy with MR 359Richard Tyc and Mark G. Torchia 22 Role of Radiofrequency Ablation and Laser-Induced Thermal Therapy in the Management of Functional Neurosurgery and Brain Lesions 377Peter Konrad, Johnie Hodge, and Manish Ranjan 23 Radiofrequency and Microwave Thermal Ablation in Cancer Therapy and the Role of Hydrodissection 391Arvind K. Chaturvedi 24 Role of High-Intensity Focused Ultrasound for Functional Neurosurgery and for the Management of Brain Lesions 403Georgios A. Maragkos, Georgios Mantziaris, Shayan Moosa, and W. Jeffrey Elias 25 Role of HIFU in Cancer Management 425Sofia Gereta, Judith Stangl-Kremser, Tenny R. Zhang, and Jim C. Hu 26 Percutaneous Cryoablation: Mechanism of Action, Clinical Applications, and Outcomes 459Ahmed Farhan, Christopher R. Bailey, and Christos Georgiades 27 Clinical Applications of Hyperthermia 483Himanshu Mishra, Ritusha Mishra, and Abhijit Mandal 28 Thermal Damage due to a Monopole Microwave Antenna 499Marta Cavagnaro and Devashish Shrivastava 29 Thermal Damage with High-Intensity Focused Ultrasound 511Devashish Shrivastava 30 Thermal Damage Due to Laser 519Rahul Goyal and Devashish Shrivastava 31 Thermal Damage Due to Hot and Cold Surfaces 525Devashish Shrivastava 32 MRI-Induced RF Heating Considerations for Devices and Accessories that are Partially in and Partially Out of the Human Body 533Ran Guo, Md Zahidul Islam, Wolfgang Kainz, and Ji Chen References 542 Index 545

    5 in stock

    £180.00

  • Precision Cancer Therapies Targeting Oncogenic

    John Wiley and Sons Ltd Precision Cancer Therapies Targeting Oncogenic

    5 in stock

    Book SynopsisTargeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies A thorough compilation of the many scientific breakthroughs in the ongoing development of precision cancer therapies related to lymphoma Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice focuses on lymphoma, an area which has seen a remarkable number of breakthroughs in the ongoing development of precision cancer therapies. Each section on a specific biology or class of drugs has an introductory chapter written by an authority in the field, exclusively focused on the science and its relevance to cancer biology. This approach addresses the need for scientists, physicians, and the private sector to understand the broader context of the extraordinary advances that have produced such astonishing advances in the disease. The work primarily focuses on how to understand and translate fundamental principles of basic science into informatiTable of ContentsList of Contributors xix Volume Foreword xxiv Volume Preface xxvi Series Preface xxviii Section I Biological Basis of the Lymphoid Malignancies 1 1 Fundamental Principles of Lymphomagenesis 3Pierre Sujobert, Philippe Gaulard, and Laurence de Leval 2 Identifying Molecular Drivers of Lymphomagenesis 12Jennifer Shingleton and Sandeep S. Dave 3 Characterizing the Spectrum of Epigenetic Dysregulation Across Lymphoid Malignancies 25Sean Harrop, Michael Dickinson, Ricky Johnstone, and Henry Miles Prince 4 Animal Models of Lymphoid Malignancies 40Anjali Mishra Section II Targeting the PI3 Kinase-AKT-mTOR Pathway 53 5 Principles of PI3K Biology and Its Role in Lymphoma 55Ralitsa R. Madsen 6 Pharmacologic Differentiation of Drugs Targeting the PI3K-AKT-mTOR Signaling Pathway 71Inhye E. Ahn, Jennifer R. Brown, and Matthew S. Davids 7 Clinical Experience with Phosphatidylinositol 3-Kinase Inhibitors in Hematologic Malignancies 86Alessandro Broccoli and Pier Luigi Zinzani 9 PI3 Kinase, AKT, and mTOR Inhibitors 113Joel McCay and John G. Gribben Section III Targeting Programmed Cell Death 131 10 Principles for Understanding Mechanisms of Cell Death and Their Role in Cancer Biology 133Sarah T. Diepstraten, John E. La Marca, David C.S. Huang, and Gemma L. Kelly 11 Pharmacologic Features of Drugs Targeting BCL2 Family Members 151Jennifer K. Lue and Owen A. O’Connor 12 Clinical Experience with Pro-Apoptotic Agents 165Thomas E. Lew and John F. Seymour 13 Promising Combinations of Drugs Targeting Apoptosis 186William G. Wierda Section IV Targeting the Cancer Epigenome 197 14 The Role of Epigenetic Dysregulation in Lymphoma Biology 199Qing Deng and Michael R. Green 15 Quantitating and Characterizing the Effects of Epigenetic Targeted Drugs 209Emily Gruber, Alexander C. Lewis, and Lev M. Kats 16 Clinical Experience with Epigenetic Drugs in Lymphoid Malignancies 225Enrica Marchi, Ipsita Pal, and John Sanil Manavalan 17 Future Prospects for Targeting the Epigenome in Lymphomas 236Yusuke Isshiki and Ari Melnick Section V Targeting the B-cell Receptor (BCR) 249 18 The Pathologic Role of BCR Dysregulation in Lymphoid Malignancies 251Jan A. Burger 19 Pharmacologic Features of Drugs Targeting Bruton’s Tyrosine Kinase (BTK) 268Joel McCay and John G. Gribben 20 Clinical Experience with Drugs Targeting Bruton’s Tyrosine Kinase (BTK) 278Julia Aronson, Anthony R. Mato, Catherine C. Coombs, Prioty Islam, Lindsey E. Roeker, and Toby Eyre 21 Promising Combinations of BTK Inhibitors with Other Targeted Agents 287Nicholas J. Schmidt, Michael E. Williams, and Craig A. Portell Section VI Protein Degraders and Membrane Transport Inhibitors 301 22 The Biological Basis for Targeting Protein Turnover in Malignant Cells 303Robert Z. Orlowski 23 Preclinical Overview of Drugs Affecting Protein Turnover in Multiple Myeloma 313Giada Bianchi, Matthew Ho, and Kenneth C. Anderson 24 Clinical Experience on Proteasome Inhibitors in Cancer 331Noa Biran, Pooja Phull, and Andre Goy 25 Targeting Nuclear Protein Transport with XPO Inhibitors in Lymphoma 361Farheen Manji, Kyla Trkulja, Rob C. Laister, and John Kuruvilla 26 Heterobifunctional Degraders for the Treatment of Lymphoid Malignancies 372Ashwin Gollerkeri, Jared Gollob, and Nello Mainolfi Section VII Novel Targets and Therapeutic Prospects in Development 381 27 Strategies for Targeting the JAK-STAT Pathway in Lymphoid Malignancies 383David J. Feith, Johnson Ung, Omar Elghawy, Peibin Yue, James Turkson, and Thomas P. Loughran Jr 28 Strategies for Targeting MYC 402Jemma Longley and Andrew Davies 29 Targeting NOTCH in Lymphoid Malignancies 411Deborah Piffaretti, Georgia Alice Galimberti, and Davide Rossi 30 Targeting NF-κB in Oncology, an Untapped Therapeutic Potential 428Matko Kalac 31 Targeting the Cell Cycle and Cyclin-dependent Kinases 444Chiara Tarantelli and Francesco Bertoni References 452 Index 457

    5 in stock

    £135.00

  • Taylor & Francis Ltd Ultrasound Assessment in Gynecologic Oncology

    Out of stock

    Book SynopsisThis innovative guide will help gynecologists or gynecologic surgeons to monitor the staging and progress of oncology treatment. An international expert here shows what office ultrasound can be used to achieve, how it correlates with other clinical findings, and how it can be integrated as necessary with other modalities and with the latest technological advances and developments in the field.Table of ContentsUltrasound scanning of the female pelvis: Normal findings. Ultrasound for differential diagnosis of adnexal masses. Ultrasound features of ovarian malignancies. Ultrasound assessment of intra-abdominal spread of ovarian cancer. Ultrasound features of endometrial cancer. Ultrasound features of uterine sarcomas. Ultrasound assessment of loco-regional spread of endometrial cancer. Ultrasound features of uterine cervical cancer. Ultrasound features of gestational trophoblastic disease. Ultrasound-guided procedures in Gynecologic Oncology. Ultrasound in vulvar and vaginal cancer.

    Out of stock

    £999.99

  • A Practical Guide to Peritoneal Malignancy

    Taylor & Francis Ltd A Practical Guide to Peritoneal Malignancy

    15 in stock

    Book SynopsisPeritoneal malignancy is a rapidly growing field within surgical oncology. National and International treatment programmes and training curricula are being established worldwide to co-ordinate treatment and management of these challenging clinical problems. A large body of evidence now exists, but the practical implications of this evidence base remain unclear. The Peritoneal Malignancy Institute in Basingstoke, the largest centre in the world, is at the forefront of  new developments and techniques. This manual combines the experience of the PMI  with the latest evidence to provide a practice-oriented guide to the successful set up and running of a peritoneal malignancy unit.Table of ContentsSET: UNDERSTANDING AND ASSESSMENT OF PERITONEAL DISEASE. Appendix tumours and pseudomyxoma peritonei: A ‘paradigm’ for peritoneal disease. Colorectal peritoneal metastases. Peritoneal mesothelioma. Miscellaneous peritoneal malignancies. Quantitative assessment of peritoneal disease. Imaging in peritoneal malignancy. DIALOGUE: INTRAPERITONEAL CHEMOTHERAPY AND CYTOREDUCTIVE SURGERY. Intraperitoneal chemotherapy. Perioperative and anaesthetic care. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Postoperative care. Postoperative complications. CLOSURE: ONGOING CARE AND FUTURE MANAGEMENT OPTIONS. Histopathological aspects of peritoneal malignancy. Follow-up protocols in peritoneal malignancy. Recurrence of pseudomyxoma peritonei. Future perspectives in peritoneal malignancy.

    15 in stock

    £84.99

  • A Practical Guide to Peritoneal Malignancy

    Taylor & Francis Ltd A Practical Guide to Peritoneal Malignancy

    15 in stock

    Book SynopsisPeritoneal malignancy is a rapidly growing field within surgical oncology. National and International treatment programmes and training curricula are being established worldwide to co-ordinate treatment and management of these challenging clinical problems. A large body of evidence now exists, but the practical implications of this evidence base remain unclear. The Peritoneal Malignancy Institute in Basingstoke, the largest centre in the world, is at the forefront of  new developments and techniques. This manual combines the experience of the PMI  with the latest evidence to provide a practice-oriented guide to the successful set up and running of a peritoneal malignancy unit.Table of ContentsSET: UNDERSTANDING AND ASSESSMENT OF PERITONEAL DISEASE. Appendix tumours and pseudomyxoma peritonei: A ‘paradigm’ for peritoneal disease. Colorectal peritoneal metastases. Peritoneal mesothelioma. Miscellaneous peritoneal malignancies. Quantitative assessment of peritoneal disease. Imaging in peritoneal malignancy. DIALOGUE: INTRAPERITONEAL CHEMOTHERAPY AND CYTOREDUCTIVE SURGERY. Intraperitoneal chemotherapy. Perioperative and anaesthetic care. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Postoperative care. Postoperative complications. CLOSURE: ONGOING CARE AND FUTURE MANAGEMENT OPTIONS. Histopathological aspects of peritoneal malignancy. Follow-up protocols in peritoneal malignancy. Recurrence of pseudomyxoma peritonei. Future perspectives in peritoneal malignancy.

    15 in stock

    £175.00

  • Lulu.com Stoma

    15 in stock

    Book Synopsis

    15 in stock

    £21.62

  • Molecules Engineered Against Oncogenic Proteins

    John Wiley & Sons Inc Molecules Engineered Against Oncogenic Proteins

    4 in stock

    Book SynopsisMolecules Engineered Against Oncogenic Proteins and Cancer A comprehensive review of the latest molecular advances in cancer treatment Featuring 91 total small molecule kinase/KRAS inhibitors, 80 of which are FDA-approved, Molecules Engineered Against Oncogenic Proteins and Cancer documents the recent scientific advances that have transformed one of medicine's most challenging areascancer treatment. Most of these inhibitors specifically block oncogene-induced carcinogenic proteins with results that have dramatically advanced the treatment of cancer. In addition, the structural formulas of more than 100 kinase/KRAS inhibitors in clinical trials are presented. With a very well-known chemist as an author, Molecules Engineered Against Oncogenic Proteins and Cancer includes information on: Each molecule's structure, function of the kinase target and relevance to cancer, the drug discovery process, and molecular details of drug action MuTable of Contents Preface vii Chapter 1. Introduction 1 1.1 Types of Protein Kinases 1 1.2 Protein Kinase Domains 1 1.3 ATP-Binding Site 2 1.4 Types of Kinase Inhibitors 3 1.5 Brief History of Smallmolecule Kinase Inhibitors 5 1.6 Peak 12-Month Sales for Leading Kinase Inhibitors 7 1.7 Approved Kinase Inhibitors 7 Chapter 2. BCR-ABL Inhibitors 18 2.1 Imatinib* (1) 19 2.2 Nilotinib* (2) 24 2.3 Dasatinib* (3) 27 2.4 Bosutinib* (4) 30 2.5 Ponatinib* (5) 33 2.6 Olvermbatinib** (6) 37 2.7 Asciminib* (7) 38 Chapter 3. BTK Inhibitors 43 3.1 Ibrutinib* (8) 45 3.2 Acalabrutinib* (9) 51 3.3 Zanubrutinib* (10) 54 3.4 Tirabrutinib** (11) 57 3.5 Orelabrutinib** (12) 58 Chapter 4. EGFR/HER Family Inhibitors 59 4.1 Gefitinib* (13) 61 4.2 Erlotinib * (14) 67 4.3 Icotinib** (15) 72 4.4 Afatinib* (16) 74 4.5 Dacomitinib* (17) 77 4.6 Osimertinib* (18) 80 4.7 Mobocertinib* (19) 86 4.8 Lapatinib* (20) 90 4.9 Tucatinib* (21) 93 4.10 Neratinib* (22) 95 Chapter 5. VEGFR/Multikinase Inhibitors 97 5.1 Sorafenib* (23) 99 5.2 Regorafenib* (24) 104 5.3 Sunitinib* (25) 106 5.4 Pazopanib* (26) 112 5.5 Axitinib* (27) 114 5.6 Nintedanib* (28) 117 5.7 Apatinib** (29) 121 5.8 Lenvatinib* (30) 122 5.9 Tovozanib* (31) 125 Chapter 6. CDK4/6 Inhibitors 127 6.1 Palbociclib* (32) 129 6.2 Ribociclib*(33) 136 6.3 Abemaciclib* (34) 139 6.4 Trilaciclib* (35) 142 Chapter 7. JAK Inhibitors 144 7.1 Tofacitinib* (36) 147 7.2 Baricitinib* (37) 151 7.3 Peficitinib** (38) 153 7.4 Upadacitinib* (39) 158 7.5 Delgocitinib** (40) 161 7.6 Filgotinib** (41) 163 7.7 Abrocitinib* (42) 166 7.8 Ruxolitinib* (43) 170 7.9 Fedratinib* (44) 173 7.10 Pacritinib* (45) 175 7.11 Ritlecitinib # (46) 177 7.12 Brepocitinib # (47) 181 7.13 Ropsacitinib # (48) 184 Chapter 8. Allosteric TYK2 Inhibitors 187 8.1 Deucravacitinib* (49) 189 Chapter 9. ALK/multikinase Inhibitors 195 9.1 Crizotinib* (50) 197 9.2 Ceritinib* (51) 202 9.3 Alectinib* (52) 205 9.4 Brigatinib* (53) 207 9.5 Lorlatinib* (54) 210 Chapter 10. BRAF/Multikinase Inhibitors 214 10.1 Vemurafenib* (55) 216 10.2 Dabrafenib* (56) 222 10.3 Encorafenib* (57) 225 Chapter 11. MEK Inhibitors 227 11.1 Trametinib* (58) 228 11.2 Cobimetinib* (59) 232 11.3 Binimetinib* (60) 235 11.4 Selumetinib* (61) 237 Chapter 12. RET/Multikinase Inhibitors 240 12.1 Vandetanib* (62) 242 12.2 Cabozantinib* (63) 245 12.3 Selpercatinib* (64) 247 12.4 Pralsetinib* (65) 251 Chapter 13. FGFR Inhibitors 253 13.1 Erdafitinib* (66) 255 13.2 Pemigatinib* (67) 260 13.3 Infigratinib* (68) 263 13.4 Futibatinib* (69) 265 Chapter 14. PI3K Inhibitors 267 14.1 Alpelisib* (70) 269 14.2 Idelalisib* (71) 273 14.3 Duvelisib* (72) 277 14.4 Umbralisib* (73) 279 14.5 Copanlisib* (74) 281 Chapter 15. TRK/Multikinase Inhibitors 284 15.1 Larotrectinib* (75) 285 15.2 Entrectinib* (76) 288 15.3 Repotrectinib # (77) 291 Chapter 16. MET Inhibitors 294 16.1 Capmatinib* (78) 295 16.2 Tepotinib* (79) 297 Chapter 17. KIT/PDGFR/Multkinase Inhibitors 299 17.1 Avapritinib* (80) 301 17.2 Ripretinib* (81) 304 Chapter 18. FLT3 Inhibitors 306 18.1 Midostaurin* (82) 308 18.2 Gilteritinib* (83) 313 Chapter 19. mTOR Inhibitors 315 19.1 Sirolimus* and Analogs (84) 317 Chapter 20. Other Kinase Inhibitors 322 20.1 Netarsudil* (85) 324 20.2 Belumosudil* (86) 326 20.3 Fostamatinib* (87) 328 20.4 Pexidartinib* (88) 331 Chapter 21. KRAS Inhibitors 335 21.1 Sotorasib* (89) 337 21.2 Adagrasib* (90) 346 21.3 Jdq443 # (91) 350 Chapter 22. An Overview of the Discovery Process for Medically Useful Inhibitors of Oncogenic Protein Kinases 353 22.1 High-quality Leads 353 22.2 Integrating Substructures from Different High Quality Leads or Established Inhibitors 355 22.3 Variation of Hinge-binding Nucleus 357 22.4 Macrocyclization 359 22.5 Fragment-based Approach 360 22.6 Covalent Inhibitors 361 22.7 Strategic Structural Modification of Prior Drugs 362 22.8 Exploiting a Specific Kinase Pocket to Optimize Selectivity 364 22.9 Solvent-exposed Appendages to Enhance Solubility and PK Properties 367 Chapter 23. Targeted Molecular Anticancer Therapies – Successes and Challenges 368 23.1 The Beginning 368 23.2 Further Developments 368 23.3 Biomarker-driven Drug Development 369 23.4 Mitigation of Drug Resistance 370 23.5 Miscellaneous Approaches 371 23.6 Discovery Chemistry 373 Appendix 1. First FDA Approvals by Year 374 Appendix 2. Kinase/KRAS Inhibitors in Development 375 Appendix 3. Visualization of Differentially Expressed Kinases in Cancer 378 Appendix 4. M & A Transactions Driven by Oncology-focused Kinase and KRAS Inhibitors 379 Appendix 5. Alphabetic List of Oncogenic Protein Inhibitors 380

    4 in stock

    £119.70

  • Dying to Be Me

    Hay House Inc Dying to Be Me

    3 in stock

    Book SynopsisIn this truly inspirational memoir, Anita Moorjani relates how, after fighting cancer for almost four years, her body began shutting down—overwhelmed by the malignant cells spreading throughout her system. As her organs failed, she entered into an extraordinary near-death experience where she realized her inherent worth . . . and the actual cause of her disease. Upon regaining consciousness, Anita found that her condition had improved so rapidly that she was released from the hospital within weeks—without a trace of cancer in her body! Within these pages, Anita recounts stories of her childhood in Hong Kong, her challenge to establish her career and find true love, as well as how she eventually ended up in that hospital bed where she defied all medical knowledge. As part of a traditional Hindu family residing in a largely Chinese and British society, Anita had been pushed and pulled by cultural and religious customs since she was a little girl. After years of struggTrade Review"I have been deeply and profoundly touched by the contents of this book, and even more so by my personal relationship with Anita Moorjani, who came into my life through a series of Divinely orchestrated coincidences." - Dr. Wayne W. Dyer"Describing her ensuing near-death experience as a realm of clarity and expansiveness, 'a state of being,' Moorjani made the choice to return, and her rapid and remarkable recovery defies all medical understanding. Her psychospiritual healing, which continues to this day, was self-realization: of her own magnificence, of oneness with universal energy and with a universe comprising. This candid memoir is a cathartic testimony to the magnificence and healing capacity of every human being." - Publishers Weekly"This book is very thought provoking. Can we take the learnings, and make the changes, from someone else's Near Death Experience? Can I create for myself the same level of faith and knowing just by reading this book? Honestly, I don't think I can. But what I can do is open my mind that little bit more, take this book as another brick in building that wall of strength, and take her learnings with me on my own journey. I recommend that you do that same." - Rachel Bell"I had the pleasure of reading Anita's book after hearing her speak in Sydney, Australia at the end of January. Her NDE experience is profound. The wisdom she shares is life changing." - Cheryl Richardson"This book reminded me how important it is to live life from a place of passion rather than from a place of fear. No matter what challenge life gives us, it's really important to look for the gift in it. This book is truly amazing." - Vibrant Living with Celine

    3 in stock

    £15.29

  • Hay House Make Room for Healing

    10 in stock

    Book Synopsis

    10 in stock

    £10.33

  • Springer-Verlag New York Inc. Bioelectromagnetics Current Concepts

    Out of stock

    Book SynopsisProceedings of the NATO Advanced Research Workshop on The Mechanisms of the Biological Effect on Extra High Power Pulses (EHPP), Yerevan, Armenia 3 - 5 March 2005Table of ContentsPreface.Acknowledgements. Chapter I. Mechanisms of EMF interactions with biological systems. Thermal vs. nonthermal Mechanisms of Interactions between Electromagnetic Fields and Biological Systems; M. Markov.- The Mechanisms Paradox; K. Foster.- Cell Aqua Medium as a Primary Target for the Effecy of Electronmagnetic Fields; S.Ayrapetyan.- The Effect of ELF EMF-Pretreated Distillated Water on Barley seed Hydration and Germination Potential; A. Amyan and S. Ayrapetyan.- Intracellular Calcium Signaling Basic Mechanisms and Possible Alterations; P. Kostyuk and E. Lukyanetz.-Suppression of Synaptic Transmission in Hippocampus by extremely-high-power Microwave Pulses Synchronized with Neuronal Excitation; J. Doyle et al.-The in vitro Assessment of Potential Genotoxicity of High Power Microwave Pulses; N. Chemeris at al.- Unconventional Approach to Biological Effects of EMF; B. Sernelius.- The Effect of Iron Ions and weak static or low Frequency(50 HZ) Magnetic Fields on Lymphocytes: free Radical Processes; J. Jajte and M. Zmyslony.-Collagen as a Target for Electromagnetic Fields. Effects of 910-mhz on Rat Brain; M. Tzaphlidou and E. Fotiou.-Animal Studies on the Effects of ELF and Static EMF; N.Seyhan et al.- Chapter II. EMF Therapy. Interactions Between Electromagnetic Fields and Immune System: Possible Mechanism for Pain Control; M.Markov et al.- Electromagnetic Field Therapy: A Role for Water?;C. Hazlewood et al.- Physiological Mechanisms Underlying Millimeter Wave Therapy; M. Ziskin.-Anti-Inflammatory Effects of low-intensity Millimeter Wave Radiation; A.Gapeyev et al.- Study of the Secretion of Melatonin and Stress Hormones in Operators from Broadcasting and TV-Stations Exposed to Radiofrequency (RF) Electromagnetic Radiation (EMR) ; M. Israel et al.-The Combining Effect of the ferrocene Compounds with electro magnetic Field ; A. F. Badawi and A.A.Hafiz.-Chapter III. EMF Dosimetry. High-Frequency Device for the Measurement of the Specific Absorbed Rate by the Biotissues of High Intensity; R. Simonyan et al.-Physical Aspects of Pulsed Microwave Absorption in Tissue; P.Šístek.- Exposure Metrics of Magnetic Fields related to Power Lines and electric Applicances T. Saito et al.-Chapter IV. Epidemiology and policy Science, Uncertainty and Policy for Power and Mobile Frequency EMF; L. Kheifets.-Risk Evaluation of Potential Environmental Hazards from low energy electromagnetic Field Exposure using sensitive In Vitro Methods; F. Adlkofer.-Can the Radiation from Cellular Phones have important Effects on the Forces between Biological-Tissue-Components?; B.E.Sernelius.-Exposure to non-ionizing radiation of personnel in Physiotherapy; M.Israel and P. Tschobanoff.- Chapter V. Posters. Changes of the Magnitude of Arteriolar Vasomotion during and after ELF-EMF Exposure in Vivo L.Traikov et al.-The Effects of SMF, EHPP and Hydrogen Peroxide on the Development of Yeasts; N. Baghdasaryan and S.Ayrapetyan.- Inhibition of Melatonin Synthesis in Human Peripheral Blood Lymphocytes by EMF: A Mechanism of Interaction? ; R.Coghill and R. Baghurst.- A Study of Melatonin in Plant Tissues and its Dietary and Health Implications; R. Baghurst and R.Coghill.-Effect of High Dilution Quinones on 02 uptake by peripheral Blood Lymphocytes: A Polarographic Study; C. Conners and R. Coghill.-Internal originators of Functions Fluctuation in Multi-Celled Organisms; R.D. Grygoryan and P.N. Lissov.-List of speakers. List of participants. Official Photograph. Index

    Out of stock

    £999.99

  • John Wiley and Sons Ltd Handbook of Clinical Obstetrics

    Out of stock

    Book SynopsisThe second edition of this quick reference handbook for obstetricians and gynecologists and primary care physicians is designed to complement the parent textbook Clinical Obstetrics: The Fetus & Mother The third edition of Clinical Obstetrics: The Fetus & Mother is unique in that it gives in-depth attention to the two patients fetus and mother, with special coverage of each patient. Clinical Obstetrics thoroughly reviews the biology, pathology, and clinical management of disorders affecting both the fetus and the mother. Clinical Obstetrics: The Fetus & Mother - Handbook provides the practising physician with succinct, clinically focused information in an easily retrievable format that facilitates diagnosis, evaluation, and treatment. When you need fast answers to specific questions, you can turn with confidence to this streamlined, updated reference.Table of ContentsContiributors. Foreword. Preface. Preface to the First Edition. Acknowledgments. Part I: Conception and Conceptus Development. 1 Early conceptus growth and immunobiologic adaptations of pregnancy (Kenneth H.H. Wong and Eli Y. Adashi). 2 Normal embryonic and fetal development (Trivedi Vidhya N. Persaud and Jean C. Hay). Part II: Pregnancy and the Fetoplacental Unit. 3 Normal and abnormal placentation (Soheila Korourian and Luis De Las Casas). 4 Fetoplacental perfusion and transfer of nutrients (Henry L. Galan and Frederick C. Battaglia). 5 Endocrinology of pregnancy and the placenta (Alan DeCherney, Jessica Spencer, Tim Chard, and Karen A. Hutchinson). Part III: Fetal Developmental Biology. 6 Fetal lung development and amniotic fluid analysis (Ian Gross and Matthew J. Bizzarro). 7 Fetal cardiovascular physiology and response to stress conditions (Jean-Claude Fouron and Amanda Skoll). 8 Fetal endocrinology (Charles E. Wood and Maureen Keller-Wood). Part IV: Variations in Embryonal and Fetal Growth and Development. 9 Sporadic and recurrent pregnancy loss (Robert M. Silver and D. Ware Branch). 10 Ectopic and heterotopic pregnancies (Arnon Wiznitzer and Eyal Sheiner). 11 Multifetal pregnancies: epidemiology, clinical characteristics, and management (Michelle Smith-Levitin, Daniel W. Skupski, and Frank A. Chervenak). 12 Biology of normal and deviant fetal growth (Andrée Gruslin and the late Carl A. Nimrod). Part V: Fetal Infections and Teratogenesis. 13 Developmental toxicology, drugs, and fetal teratogenesis (Robert L. Brent and Lynda B. Fawcett). 14 Drugs, alcohol abuse, and effects in pregnancy (Stephen R. Carr and Donald R. Coustan). 15 Teratogenic viruses (Antonio V. Sison). 16 Transplacentally acquired microbial infections in the fetus (Santosh Pandipati and Ronald S. Gibbs). 17 Antibiotics and other antimicrobial agents in pregnancy and during lactation(Janet I. Andrews and Jennifer R. Niebyl). Part VI: Fetal Diseases. 18 Principles of human genetics: chromosomal and single-gene disorders (Joe Leigh Simpson and Maurice J. Mahoney). 19 Basic principles of ultrasound (Mladen Predanic, Frank A. Chervenak, and E. Albert Reece). 20 Prenatal diagnosis of central nervous system malformations (Gianluigi Pilu and Sandro Gabrielli). 21 Prenatal diagnosis of thoracic and cardiac abnormalities (Gianluigi Pilu, Philippe Jeanty, and Juliana M.B. Leite). 22 Gastrointestinal and genitourinary anomalies (Sandro Gabrielli, Nicola Rizzo, and E. Albert Reece). 23 Fetal skeletal anomalies (Luís F. Gonçalves, Patricia L. Devers, Jimmy Espinoza, and Roberto Romero). 24 First- and second-trimester prenatal diagnosis (John C. Hobbins). 25 First- and second-trimester screening for open neural tube defects and Down syndrome (James E. Haddow, Glenn E. Palomaki, and Ronald J. Wapner). Part VII: Methods of Evaluation of Fetal Development and Well-being. 26 Prenatal diagnosis of deviant fetal growth (E. Albert Reece and Zion J. Hagay). 27 Three- and four-dimensional ultrasound and magnetic resonance imaging in pregnancy (Teresita L. Angtuaco). 28 Doppler ultrasonography and fetal well-being (Brian J. Trudinger). 29 Antepartum and intrapartum surveillance of the fetus and the amniotic fluid (Lami Yeo, Michael G. Ross, and Anthony M. Vintzileos). Part VIII: Fetal Therapy. 30 The fetus at surgery (Robert H. Ball and Michael R. Harrison). 31 Fetal medical treatment (Mark I. Evans, Yuval Yaron, Charles S. Kleinman, and Alan W. Flake). Part IX: Maternal Biological Adaptations to Pregnancy. 32 Maternal biological, biomechanical, and biochemical changes in pregnancy (Edward K.S. Chien and Helen Feltovich). 33 Maternal nutrition (Barbara Luke). Part X: Maternal Diseases Complicating Pregnancy. 34 Trauma, shock, and critical care obstetrics (Erin A.S. Clark, Gary A. Dildy, and Steven L. Clark). 35 Hypertensive diseases in pregnancy (Frederick U. Eruo and Baha M. Sibai). 36 Cardiac diseases in pregnancy (Kjersti Aagaard-Tillery and Steven L. Clark). 37 Maternal pulmonary disorders complicating pregnancy (Steven L. Clark and Calla Holmgren). 38 Diabetes mellitus in pregnancy (Carol J. Homko, Zion J. Hagay, and E. Albert Reece). 39 Endocrine disorders in pregnancy (Fred H. Faas). 40 Gastrointestinal diseases complicating pregnancy (Washington Clark Hill and Alfred D. Fleming). 41 Liver disease in pregnancy (Vivek Raj). 42 Pregnancy complicated by renal disorders (Michelle W. Krause and Sudhir V. Shah). 43 Neurological disorders in pregnancy (R. Lee Archer, Stacy A. Rudnicki, and Bashir S. Shihabuddin). 44 Thromboembolic disorders of pregnancy (Michael J. Paidas, Christian M. Pettker, and Charles J. Lockwood). 45 Coagulation and hematological disorders of pregnancy (Carl P. Weiner and Chien Oh). 46 Maternal alloimmunization and fetal hemolytic disease (Anita C. Manogura and Carl P. Weiner). 47 Maternal infections, human immunodeficiency virus infection, and sexually transmitted diseases in pregnancy (Richard L. Sweet and Howard Minkoff). 48 Rheumatologic and connective tissue disorders in pregnancy (Gustavo F. Leguizamón and E. Albert Reece). 49 Dermatologic disorders during pregnancy (Thomas D. Horn and Jerri Hoskyn). 50 Cancer and other neoplasms in pregnancy (Peter E. Schwartz and Masoud Azodi). Part XI: Medicosocial Considerations in Pregnancy. 51 Pregnancy before age 20 years and after age 35 years (Helen H. Kay). 52 Essentials in biostatistics and perinatal epidemiology (Paula K. Roberson and Benjamin P. Sachs). 53 Sexuality in pregnancy and the postpartum period (Kirsten von Sydow). 54 Psychiatric problems during pregnancy and the puerperium (Linda L.M. Worley and Jennifer L. Melville). 55 Ethical and legal dimensions of medicine of the pregnant woman and fetus (Judith L. Chervenak, Frank A. Chervenak, and Laurence B. McCullough). Part XII: Obstetric and Peripartal Events. 56 Bleeding in the third trimester (Lawrence W. Oppenheimer and the late Carl A. Nimrod). 57 Normal and abnormal labor (Wayne R. Cohen). 58 Operative vaginal delivery (Edward R. Yeomans). 59 Preterm labor (Erol Amon and Thomas D. Myles). 60 Prelabor rupture of the membranes (Joaquin Santolaya-Forgas, Roberto Romero, Jimmy Espinoza, Offer Erez, Lara A. Friel, Juan Pedro Kusanovic, Ray Bahado-Singh, and Jyh Kae Nien). 61 Prolonged pregnancy (Curtis L. Lowery and Paul Wendel). 62 Anesthesia in the high-risk patient (Danny Wilkerson and Richard B. Clark). 63 Puerperium and lactation: physiology of the reproductive system (Judy M. Hopkinson, Pamela D. Berens, and E. Albert Reece). Part XIII: The Newborn Infant. 64 Premature birth and neurological complications (Alan Hill). 65 Common problems of the newborn (Fernando R. Moya and Matthew Laughon). Index.

    Out of stock

    £100.76

  • ABC of Colorectal Cancer

    John Wiley & Sons Inc ABC of Colorectal Cancer

    1 in stock

    Book SynopsisColorectal cancer is a common cause of morbidity and mortality in which prevention, screening and early detection are vital. Beginning with the patient perspective and following the patient pathway, this new second edition covers epidemiology and prevention, screening programmes, decision support networks, the role of primary care, and supportive care for patients with colorectal cancer. The ABC of Colorectal Cancer provides the core knowledge on clinical genetics, diagnosis, imaging, therapy and surgery options and the latest evidence based guidelines for treating and managing colorectal cancer patients within the multidisciplinary team. Highly illustrated and accessible, it covers the full spectrum of the disease to provide the basis to make a real difference to clinical management. This is an invaluable practical guide for the non-specialist on all aspects of colorectal cancer, and is ideal for general practitioners, junior doctors, nurses and allied health professTrade Review“This short clinical review book of CRC strikes an excellent balance being both concise but with thorough and up-to-date coverage of the subject matter. The chapters based on their size, layout, and supporting figures are very approachable and I would suspect the book to be very useful to its intended audience of general practitioners and physicians in training. The text would seem to be most useful to those practicing clinical medicine, but could also serve as supplemental reading for those preparing for board-type examinations.” (Gastroenterology, 1 August 2012) “The information in the ABC of Colorectal Cancer is very well presented and the coverage is more than a GP would need in clinical practice.” (Australian Family Physician, 4 April 2012)Table of ContentsContributors vii Preface ix 1 The Patient Perspective 1 Kevin Bond 2 Epidemiology and Prevention 4 Peter Boyle, Patrick Mullie, Maria Paula Curado and David Zaridze 3 Pathways of Carcinogenesis 8 Michael Christie and Oliver Sieber 4 Clinical Genetics in the Management of Colon Cancer 13 Kai Ren Ong, Vicky Bowyer and Trevor Cole 5 Screening for Colorectal Cancer 19 Julietta Patnick and Wendy S. Atkin 6 Decision Support Networks 22 Matthew Kelly, Mark Austin and Sir Michael Brady 7 Pathology of Colorectal Cancer 26 Mohammad Ilyas 8 Imaging of Colorectal Cancer 31 Andrew Slater 9 The Role of Primary Care 36 Sue Wilson and Richard Hobbs 10 Radiotherapy for Rectal Cancer 40 Andrew Weaver 11 Surgical Interventions 44 Shazad Ashraf and Neil Mortensen 12 Adjuvant Therapy 48 Zenia Saridaki-Zoras and David Kerr 13 Treatment of Advanced Disease 52 David Watkins and David Cunningham 14 Innovative Treatment for Colorectal Cancer 58 Joanne L. Brady and David Kerr 15 Supportive Care for Patients with Colorectal Cancer 63 Pauline McCulloch and Annie Young 16 Follow-up 69 John Primrose Index 74

    1 in stock

    £24.65

  • Focal Therapy in Prostate Cancer

    John Wiley and Sons Ltd Focal Therapy in Prostate Cancer

    1 in stock

    Book SynopsisThis book comprehensively reviews the potential of focal therapy and discusses why the changing face of prostate cancer warrants a change in the way we treat men with the disease. It deals with the mechanisms by which disease can be localized within the gland and then the different technologies used for focal ablation.Trade Review“Whilst the book is not designed to represent a daily reference guide for the majority of the urological fraternity, it clearly does what it sets out to do; provide an up-to-date and comprehensive analysis of a treatment option that perhaps one day we will routinely consider alongside active surveillance and robotic surgery.” (Urology News, 1 November 2012)Fokaltherapie bedeutet Heilung und Organerhalt bei Männern mit lokal begrenztem Prostatakarzinom. Von einem internationalen Team führender Urologen, Onkologen, Radiologen und Pathologen geschrieben, bietet dieses Handbuch einen umfassenden evidenzbasierten Überblick über diese aufsehenerregende neue Therapieform.Table of ContentsContributor List, vii Preface, xi Section I Is there a role for Focal Therapy in Localised Prostate Cancer?, 1 1 The Rationale for Focal Therapy of Prostate Cancer, 3 Cole Davis, Matthew Cooperberg, and Peter R. Carroll 2 Factors That Affect Patients' Choice of Treatment, 11 Deb Feldman-Stewart and Michael D. Brundage 3 Histological Trends and the Index Lesion in Localized Prostate Cancer, 17 Vladimir Mouraviev, Thomas Wheeler, and Thomas J. Polascik 4 Selection Criteria for Prostate Cancer Focal Therapy, 29 Rajat K. Jain, Timothy K. Ito, and Samir S. Taneja Section II How can we accurately locate cancer within the gland?, 37 5 Localisation of Cancer within the Gland: Biopsy Strategies, 39 Winston E Barzell and Rodrigo Pinochet 6 Localisation of Cancer within the Gland: Ultrasound Imaging, 47 Ulrich Scheipers 7 Localization of Cancer within the Prostate: Dynamic Contrast-Enhanced MRI, 55 Philippe Puech, Anwar Padhani, Laurent Lemaitre, Nacim Betrouni, Pierre Colin, and Arnauld Villers 8 Localization of Cancer within the Gland: Diffusion-Weighted Magnetic Resonance Imaging of the Prostate, 66 Sophie F Riches, Nina Tunariu, and Nandita M deSouza 9 The future of Molecular and Biomolecular Imaging in Prostate Cancer, 75 Michael S. Gee and Mukesh G. Harisinghani Section III How can we create discrete tissue necrosis?, 85 10 Energies for Focal Ablation: Cryoablation, 87 John F. Ward 11 Focal Salvage Cryoablation in Recurrent Prostate Cancer, 98 Katsuto Shinohara 12 High-Intensity Focused Ultrasound, 106 Hashim Uddin Ahmed and Mark Emberton 13 Energies for Focal Ablation: Photodynamic Therapy, 114 Caroline M. Moore, Nimalan Arumainayagam and Mark Emberton 14 Focal Therapy for Prostate Cancer Using Radiation, 126 Irving Kaplan, Elizabeth Genega and Neil Rofsky 15 Image Registration and Fusion for Image-Guided Focal Ablation, 132 Dean Barratt and David Hawkes Section IV How can we determine the success of Focal Therapy? , 143 16 Determining Success of Focal Therapy: Biochemical and Biopsy Strategies, 145 Al Barqawi, Paul Maroni, and David Crawford 17 Determining Success of Focal Therapy: Imaging, 153 Alex Kirkham and Clare Allen 18 Evaluating Focal Therapy: Future Perspectives, 170 Hashim Uddin Ahmed and Mark Emberton Index, 179 Colour plate section can be found facing page 116

    1 in stock

    £90.86

  • Cancer and the Search for Selective Biochemical

    Taylor & Francis Inc Cancer and the Search for Selective Biochemical

    Out of stock

    Book SynopsisThe world of medicine has become splintered into two factions, that of orthodoxy and its counterpart, alternative or complementary medicine. A problem with alternative medicine is, of course, that of anecdote and hearsay. The solution: the disclosure, in an unassailable fashion, of the underlying biochemical principles for alternative cancer therapies. Cancer and the Search for Selective Biochemical Inhibitors, Second Edition delineates the underlying biochemical principles for alternative cancer therapies. Completely revised and updated, this edition includes coverage of the link between concepts and practices of alternative and conventional medicine. The author examines anticancer plant substances and other alternatives such as Vitamin C, essiac tea, shark cartilage, and cat's claw. The text also addresses the problem of determining selective and non-toxic enzyme inhibitors for cancer cell metabolic pathways. While an increased number of allopathic professionals are in tTable of ContentsCrossroads. Cancer Origins and Characteristics. Biochemical Insights. Starting at the Genetic Level. Enzymatic Biochemical Treatment Protocols. The Alternative Scene. Surveying Anticancer Plant Substances. On Overcoming the Intractability of Cancer. Cancer Esoterica. The Inhibition of Cancerous Stem Cells. A Summing Up.

    Out of stock

    £999.99

  • Myelodysplastic Syndromes

    Taylor & Francis Inc Myelodysplastic Syndromes

    Out of stock

    Book SynopsisWritten by a team of leading authorities in pathogenesis, diagnostic techniques, and clinical management strategies in myelodysplastic syndrome (MDS), this text provides a concise, easy-to-follow review of the advances in the science, classification, diagnosis, and management of the condition. An ideal source for hematologists, oncologists, and cancer researchers, this Second Edition features: a new eight-page color insert 200 color and black-and-white illustrations reworked content organized into three sections: MDS epidemiology and biology; diagnosis, classification, and prognosis; and MDS therapy thoroughly updated chapters reflecting a shift from the topical focus as dictated by the evolution of the field New topics in Myelodysplastic Syndrome include: del(5q) and 5q-syndrome, CMML, and MDS-MPD overlap syndrome the reborn DNA meTable of Contents1. Myelodysplastic Syndrome: Historical Aspects and Classification. 2. Epidemiology of MDS. 3. Cytogenetics & Molecular Biology of MDS. 4. Global Genomic Approaches to MDS. 5. The Role of Apoptosis in MDS. 6. The Role of Mitochondria in MDS. 7. Defects in Iron Metabolism and Iron Overload in MDS. 8. Therapy-Related MDS and Myeloid Leukemia. 9. Diagnosis of MDS: Criteria and Challenges. 10. Hypocellular MDS and Hypocellulcar Acute Myeloid Leukemias: Relationship to Aplastic Anemia. 11. Diagnostic Utility of Flow Cytometry. 12. Deletion 5q and 5q-Syndrome in MDS. 13. CMML and MDS-MPD Overlap Syndromes. 14. MDS in Children. 15. Prognostic Factors in the Assessment of Patients with MDS. 16. Therapeutic Strategies: The Approsch to Care of Patients w/ MDS, and Criteria for Response. 17. Management of Cytopenias in MDS. 18. Immune Dysregulation And The Role For Immunotherapy in Myelodysplastic Syndrome (MDS). 19. Lenalidomide Therapy in MDS. 20. DNA Methyltransferase Inhibitor Therapy in MDS. 21. Intensive Chemotherapy and Stem Cell Transplantation in MDS.

    Out of stock

    £999.99

  • Pancreatic Cancer

    Johns Hopkins University Press Pancreatic Cancer

    1 in stock

    Book SynopsisThe authors hope that their honest yet hopeful perspective will help all people with cancer and those who care about them.Trade ReviewAn authoritative manual of instructions... This book is highly recommended. -- M. G. Paregian Brief (at just 171 pages) but powerful, this straightforward book is both sobering and inspiring. Hopkins Medicine No matter how experienced a professional might be in dealing with patients with pancreatic cancer, it is refreshing to hear from the patient's perspective, reading how they navigate through the system before they land in our clinic and receive our care. Overall, I would recommend this book to all health professionals who care for patients with pancreatic cancer (both novice and seasoned), as well as those who are adjusting to a diagnosis of pancreatic cancer. -- Raymond Chan Cancer Forum This book is excellent. It is positive and compassionate... It would make a useful contribution to a library. Macmillan Cancer Support This book is a valuable source of intimate details about Pancreatic Disease and related problems... Highly recommended for the practicing instructions and frank discussions of personal and family preparation along with the current treatments that are available. M. G. ParegianTable of ContentsPreface1. The Gathering Clouds2. What Is Pancreatic Cancer and What Are Its Symptoms?3. The Fight Begins4. The Initial Treatment5. The Prospect of Death6. Balancing Hope and Truth7. Family and Friends8. Managing the Symptoms of Advanced Cancer9. A New Approach to Living10. Next Steps11. What We've Learned from Our ExperienceAppendix: Supplemental InformationNotesIndex

    1 in stock

    £18.05

  • Confronting Hereditary Breast and Ovarian Cancer

    Johns Hopkins University Press Confronting Hereditary Breast and Ovarian Cancer

    1 in stock

    Book SynopsisWith its unique combination of the latest research, expert advice, and compelling personal stories, this book gives previvors, survivors, and their family members the guidance they need to face the unique challenges of hereditary cancer.Trade ReviewA fine resource discussing the challenges of living in a high-risk body. Midwest Book Review An insightful and informative read. Nursing Times A top pick for any breast cancer collection. Midwest Book Review This book is an excellent resource for lay people trying to understand and deal with inherited breast and ovarian cancer. -- Judith Offman Journal of Family Planning and Reproductive HealthcareTable of ContentsForeword by Mark H. Greene, M.D.AcknowledgmentsIntroductionPart I: Understanding Cancer, Genetics, and Risk1. Breast and Ovarian Cancer BasicsMost Cancers Aren't HereditaryAn Introduction to Breast CancerAn Introduction to Ovarian CancerOther Hereditary Cancers2. A Peek Inside: Your Genes at WorkThe Evolution of Genetic Discovery: From Peas to BRCAYour Genetic ABCs . . . and a DMutations: Spelling Errors in Your DNA CookbookHow Mutations Lead to CancerWhat's So Special about BRCA?3. Defining RiskMaking Sense of StatisticsGetting Personal: Factors That Modify Your RiskIt's a Numbers Game4. Hereditary Cancer: What's Swimming in Your Gene Pool?Mutations from Mom or DadHidden Risk in the Family TreeHBOC and Other Hereditary Cancer SyndromesPlotting Your Genetic PedigreePart II: Assessing Your Risk5. Genetic CounselingThe Value of CounselingWhat to Expect from the ProcessWhy You Need an Expert to Unravel Your Genetic HistoryDeciding Who Should Test First6. Genetic Testing: Facing Your Hereditary HoroscopeWhich Test Is Right for You?Powerful, Yet ImperfectIssues for Survivors and Women in Treatment7. Decoding Your Test ResultsLife, Interrupted: It's PositiveGood News! You're a True NegativeWhen No Might Mean MaybeGenetic VariantsNow What? Implications for You and Your FamilyPart III: Managing Your Risk: Your DNA Doesn't Have to Be Your Destiny8. Early Detection StrategiesHigh-Risk Surveillance for Breast CancerHigh-Risk Surveillance for Ovarian CancerIs It Cancer?Screening for Other Hereditary Cancers9. ChemopreventionRisk-Reducing Medications for Breast CancerAlternatives under StudyChemoprevention for Ovarian Cancer10. Mastectomy for Risk Reduction and TreatmentReducing Cancer Risk by Removing the BreastsSkin-Sparing ProceduresTreating Breast Cancer with MastectomyWho Should Perform Your Surgery?Risks and Recovery11. Reconstruction: New Breasts after MastectomyDelaying Reconstruction to Complete Breast Cancer TreatmentLiving with a Flat ChestSaline and Silicone ImplantsOptions for Using Your Own TissueOptional Last Steps: Adding Nipples and AreolasGreat Expectations: Surgery and RecoveryChoosing the Right Surgeon12. Oophorectomy and Other Risk-Reducing Gynecologic SurgeriesOophorectomy ProceduresShould You Have a Hysterectomy Too?Oophorectomy, Mastectomy: Either, Neither, or Both?Issues for Breast Cancer Survivors13. Dealing with Menopause and Quality-of-Life IssuesSymptoms of Surgical MenopauseLong-Term Side EffectsShould You Take Hormones?Issues for Breast Cancer SurvivorsPart IV: Living with BRCA: Issues and Answers14. Managing Lifestyle ChoicesThe Three-Legged Stool: Nutrition, Weight, and Physical ActivityAlcohol: An Unwise ChoiceOther Lifestyle Risk Factors15. Sharing Information with Friends, Family, and CoworkersSharing Risk and Genetic Testing Information with FamilyIssues for Spouses, Partners, and People You DateWhat Should You Tell Employers and Coworkers?16. Young and at High RiskShould You Consider Testing Now?Diagnostic DifficultiesDealing with a Diagnosis before MenopausePlanning Your Family, Preserving Your FertilityOophorectomy in Young WomenSorting through Emotions17. How BRCA Affects MenMen Get Breast Cancer TooHigh Risk for Prostate CancerOther BRCA-Related Cancers18. Diagnosis: Hereditary CancerHow Important Is a Second Opinion?Treating Hereditary CancersMaking Breast Cancer Treatment DecisionsOvarian Cancer IssuesThe Importance of Clinical Trials19. Putting the Pieces Together to Make Difficult DecisionsStart at the Beginning: Should You Be Tested?Making Decisions to Reduce Your RiskMaking Decisions about TreatmentFrom Confused to Clear in Fifteen StepsNotesIndex

    1 in stock

    £37.35

  • Before and After Cancer Treatment

    Johns Hopkins University Press Before and After Cancer Treatment

    7 in stock

    Book SynopsisWherever they are in their own journey with cancer, readers will find here a personal, practical, and powerful guide to recovery.Trade ReviewThe key to the book's success, is the mixture of compassionate wisdom and intelligent advice derived from the author's unique perspective. American Reference Books Annual It just has everything in this book and the author is meticulous to detail... Although written for a US market this book is extremely valuable for the UK healthcare setting too. The book is well referenced at the end of each chapter. Nursing TimesTable of ContentsAcknowledgments1. Get Your Life Back on Track2. Understand Physical Healing3. Dare to Dream Again4. Prioritize What You Do and Pace Yourself5. Seek Help from Conventional Medicine6. Explore Eastern and Other Medical Systems7. Dance, Skip, and Walk: Exercise Your Way Back to Health8. Nourish Your Body9. Fight Fatigue10. Ease Your Pain11. Monitor Your Mood12. Tap into Your Spirituality13. Love and Be Loved14. Surmount Setbacks15. Look What's on the HorizonAfterwordAppendixIndex

    7 in stock

    £14.72

  • Before and After Cancer Treatment

    Johns Hopkins University Press Before and After Cancer Treatment

    10 in stock

    Book SynopsisWherever they are in their own journey with cancer, readers will find here a personal, practical, and powerful guide to recovery.Trade ReviewThe key to the book's success, is the mixture of compassionate wisdom and intelligent advice derived from the author's unique perspective. American Reference Books Annual It just has everything in this book and the author is meticulous to detail... Although written for a US market this book is extremely valuable for the UK healthcare setting too. The book is well referenced at the end of each chapter. Nursing TimesTable of ContentsAcknowledgments1. Get Your Life Back on Track2. Understand Physical Healing3. Dare to Dream Again4. Prioritize What You Do and Pace Yourself5. Seek Help from Conventional Medicine6. Explore Eastern and Other Medical Systems7. Dance, Skip, and Walk: Exercise Your Way Back to Health8. Nourish Your Body9. Fight Fatigue10. Ease Your Pain11. Monitor Your Mood12. Tap into Your Spirituality13. Love and Be Loved14. Surmount Setbacks15. Look What's on the HorizonAfterwordAppendixIndex

    10 in stock

    £35.10

  • Living with Lymphoma

    Johns Hopkins University Press Living with Lymphoma

    1 in stock

    Book SynopsisThe book includes suggestions for further reading, including the latest material available online.Trade ReviewHighly recommended for any patient or family member seeking a clear health book with the latest facts. Midwest Book Review Reading [ Living with Lymphoma] is an enlightening experience and all nurses caring for lymphoma patients should ensure it is on their reading list. Nursing Standard I strongly recommend this book for relatives and friends with a diagnosis of cancer. Reference ReviewsTable of ContentsForeword, by W. Jeffrey Baker, MDPreface to the Second EditionPreface to the First EditionIntroduction, by Michael R. Bishop, MDPart I1. What Is Lymphoma?2. Symptoms and DiagnosisPart II3. Chemotherapy4. Radiation Therapy and Surgery5. Monoclonal Antibodies and Other Magic Bullet Therapies6. Stem Cell Transplants7. Unconventional Therapies8. SurvivorshipPart III9. Basic Cell Biology and Cancer10. The Immune System11. Lymphoma Classification and Staging12. Possible Causes of LymphomaAfterwordAcknowledgmentsGlossaryIndex

    1 in stock

    £20.25

  • Living with Cancer

    Johns Hopkins University Press Living with Cancer

    1 in stock

    Book SynopsisPatients at every stage will find Living with Cancer a comprehensive, thoughtful, and accessible guide for navigating the illness and its treatment.Trade ReviewAn unusually comforting and genuinely useful resource. Booklist For anyone who has been diagnosed with cancer, or for those who have friends of family facing this illness, this guide will be an extremely invaluable resource. Patients at any stage of the disease will find rich, useful information that can help them cope more effectively with their illness. Foreword ReviewsTable of ContentsChapter 1: How am I Going to Get Through This? Part I: Making Sense of Your DiagnosisChapter 2: Setting the Goals of TreatmentChapter 3: Understanding the Biology of CancerChapter 4: What Is a Liquid Tumor?Chapter 5: How to Prepare for TreatmentChapter 6: Tests and Scans in TreatmentChapter 7: How Am I Supposed to Cope with This?Chapter 8: How Do I Cope with Changes in My Body? Part II: Managing Symptoms and Side EffectsChapter 9: Controlling NauseaChapter 10: Managing Constipation, Diarrhea, and Bowel ObstructionChapter 11: Minimizing PainChapter 12: Should I Worry about Shortness of Breath?Chapter 13: What If I'm Losing Weight?Chapter 14: What if I Have a Sudden Fever?Chapter 15: Bleeding and Clotting IssuesChapter 16: Why am I So Exhausted?Chapter 17: Why Do People Keep Asking if I Am Depressed or Anxious?Chapter 18: How Does Cancer Affect My Brain? Part III: Dealing with Progressing CancerChapter 19: They Tell Me the Cancer Is ProgressingChapter 20: Living and Hoping with Advancing CancerChapter 21: What About Practical Concerns?Chapter 22: My Doctor Says that Chemotherapy Is No Longer EffectiveChapter 23: My Body Feels Like It's Shutting DownChapter 24: What Is a Good Death? Index7

    1 in stock

    £42.75

  • Cancer with Hope

    Johns Hopkins University Press Cancer with Hope

    5 in stock

    Book SynopsisThis practical, compassionate, and inspiring book helps people with cancer navigate the often complex and difficult journey from diagnosis through treatment and life after disease. It illuminates the challenges associated with a cancer diagnosis and provides inspiration and guidance to help you not only to find the right doctors and care plan but also to cultivate hope and purpose. In Cancer with Hope, former CEO Mike Armstrong chronicles his experience with leukemia, prostate cancer, near-fatal sepsis, and a crippling autoimmune disease. Mike shares how his often difficult journey from humble beginnings to leading some of the world's top corporations taught him the importance of hope and purpose, tools that proved invaluable throughout his cancer journey. More than the tale of one man's experience with cancer, this important book includes expert advice and vetted resources to help patients best manage their disease, as well as compelling stories from a wide range of cancer patientTable of ContentsForeword, by Theodore DeWeese, MDPrologueChapter 1Patient Story: Christine HogdonChapter 2Patient Story: David GobinChapter 3Physician Story: Dr. Nilo AzadChapter 4Chapter 5Patient Navigator Story: Jill MullChapter 6Patient Story: David GobinChapter 7Patient Story: Christine HogdonChapter 8Chapter 9Nurse Story: Anna FergusonChapter 10Patient Story: Gillian LichotaChapter 11Patient Story: Leslie Reis Chapter 12Patient Story: Christine HogdonChapter 13Patient Story: David GobinChapter 14Caregiver Story: Vonda CowlingChapter 15EpilogueAcknowledgmentsResourcesGlossarySources CitedIndex

    5 in stock

    £38.70

  • Comprehensive Guide to Supportive and Palliative

    Johns Hopkins University Press Comprehensive Guide to Supportive and Palliative

    Book SynopsisTable of ContentsList of Figures and TablesList of ContributorsAcknowledgmentsIntroductionPart I. A Team ApproachChapter 1. Early Days with Molly E. Collins, MDChapter 2. Working with Patients' Families with Arden O'Donnell, MPH, MSW, LICSW, APHSW-CChapter 3. Spiritual Care in Palliative Care with Rev. Katie Pakos Rimer, MDiv, EdD, BCCChapter 4. Sexuality, Intimacy, and Cancer with Amanda Moment, MSW, LICSWChapter 5. Advancing Disease with Molly E. Collins, MDPart II. Pain Control, Symptom Management, and Psychological ConsiderationsChapter 6. Assessing the Patient in PainChapter 7. Pharmacologic Management of Cancer PainChapter 8. Nonpharmacologic Strategies in Palliative CareChapter 9. Psychological Considerations with Hermioni L. Amonoo, MD, MPPChapter 10. Managing Other Distressing ProblemsPart III. End of Life and BereavementChapter 11. Approaching the End: Concerns of Patients and Their Families at the End of LifeChapter 12. The Last DaysChapter 13. Bereavement with Bethany-Rose Daubman, MDIndex

    £62.00

  • Prostate Cancer  Expert Advice for Helping Your

    Johns Hopkins University Press Prostate Cancer Expert Advice for Helping Your

    2 in stock

    Book SynopsisTable of ContentsAcknowledgmentsIntroduction1. A Partner Tells Her Story2. The Prostate Gland: What, Where, and Why3. An Introduction to Cancer4. The Symptoms of Prostate Cancer5. Diagnosing Prostate Cancer6. The PSA Test: What It Is and What It Tells7. How a Prostate Cancer Diagnosis Can Affect You8. How a Prostate Cancer Diagnosis Can Affect Your Partner9. Treating Localized Prostate Cancer10. Treating Advanced Prostate Cancer11. Clinical Trials and Alternative Treatments12. Prostate Cancer Surgery; Before, During, and After13. The Side Effects and After-Effects of Treatments14. Sharing Information about His Cancer15. The Benefits of Diet and Exercise16. The Role of Supplements17. The Power of Prayer18. The Helpfulness of Mindfulness19. Managing the Expenses of Prostate Cancer20. Planning for DyingConclusionAppendixGlossaryAbout the AuthorsIndex

    2 in stock

    £37.35

  • Elsevier Health Sciences Textbook of Interdisciplinary Pediatric

    Out of stock

    Book SynopsisIntends to inform interdisciplinary teams about palliative care of children with life-threatening illness. This title addresses domains such as language and communication, symptoms and quality of life, and the spectrum of life-threatening illnesses. It shows how a collaborative, interdisciplinary care strategy benefits patients and their families.Table of ContentsFundamentals Needs Assessment Interdisciplinary Care and Symptom Control The Team Approach and the Family Research and education

    Out of stock

    £60.29

  • Simon & Schuster The Emperor of All Maladies A Biography of Cancer

    Out of stock

    Book Synopsis

    Out of stock

    £25.60

  • Simon & Schuster The Emperor of All Maladies A Biography of Cancer

    Out of stock

    Book Synopsis

    Out of stock

    £16.50

  • Radioguided Surgery

    Springer-Verlag New York Inc. Radioguided Surgery

    1 in stock

    Book SynopsisThis multidisciplinary textbook is designed to be the standard on the subject and is geared for use by physicians who are involved in the care and/or diagnosis of cancer patients. A wealth of illustrations, including a full-color insert, enhances the application of new concepts.Trade ReviewFrom the reviews: "This is a multidisciplinary book covering all aspects of radioisotope guided surgery for all practitioners involved in the field. The book distinguishes itself from others in the field by the clarity and breadth of explanation … . This is intended primarily for those actually involved in the field -- not just surgeons, but all physicians involved in the care of cancer patients … . Practitioners and trainees in the subspecialty fields of surgical oncology, endocrine surgery, nuclear medicine, and pathology will find it of use." (Carol EH Scott-Conner, MD, PhD, Doody’s Review Service, March, 2008) "This is a new, updated publication, which has the merit of giving wide and deep information about a field, radioguided surgery … . It is designed with a multidisciplinary approach and addressed not only to nuclear physicians but also to surgeons, oncologists, pathologists … . In conclusion, the book is an original and effective publication that we recommend to all physicians both qualified and in training, including students, who are already working in the field … ." (Vincenzo Cuccurullo and Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, 2009)Table of Contents*Anatomy and physiology of lymphatic circulation as it relates to metastatic spread of solid cancers *The role of lymph node staging for clinical decision making in patients with solid cancers *Techniques to identify sentinel lymph nodes in patients with: Breast cancer, Melanoma, Penile carcinoma, Head and neck cancer, Ovarian cancer, Vulvar cancer, Endometrial cancer, Cancers of the gastrointestinal tract and pancreas, Neuroendocrine tumors, Prostate cancer, Non-small cell lung cancer *Histopathology of sentinel lymph nodes: Imprint cytology in sentinel lymph node biopsy, Conventional histology and immunohistochemistry, Molecular biology techniques for sentinel lymph nodes *Non-sentinel-node applications of radioguided surgery: Breast cancer, Parathyroid tumors, Neuroendocrine tumors, Solitary lesions in the lung, Thyroid cancer, Present role of radioimmunoguided surgery *The perspective of the nuclear medicine physician, the surgeon, and the pathologist *Radiopharmaceuticals for radioguided surgery *Instrumentation: Physical performance parameters of intraoperative probes, and other technical issues of radioguided surgery, Imaging probes and positron-sensitive probes *Radiation protection issues in radioguided surgery *Training and credentialing for radioguided surgery

    1 in stock

    £89.99

  • ABC of Prostate Cancer

    John Wiley & Sons Inc ABC of Prostate Cancer

    10 in stock

    Book SynopsisProstate cancer is the most common cancer in men in the UK and US and the second most common worldwide. The ABC of Prostate Cancer provides fully illustrated guidance on the treatment and management of prostate cancer. It covers the biology, anatomy, and pathology of prostate cancer, screening, and active surveillance and monitoring.Table of ContentsContributors vii Foreword ix 1 Applied Anatomy of the Prostate 1Prasanna Sooriakumaran Karl-Dietrich Sievert Abhishek Srivastava and Ashutosh Tewari 2 Pathology of Prostate Cancer 5Murali Varma and Ashish Chandra 3 Biology of Prostate Cancer 8R. William G. Watson and John M. Fitzpatrick 4 Prostate Cancer Diagnosis 11Robin Weston Anthony J. Costello and Declan G. Murphy 5 Imaging of Prostate Cancer 14James Halls and Uday Patel 6 Screening for Prostate Cancer 18Richard J. Bryant and Freddie C. Hamdy 7 Active Surveillance 22Judith Dockray Pardeep Kumar Lars Holmberg and Gordon Muir 8 Open Radical Prostatectomy 25Wim van Haute and Hein van Poppel 9 Laparoscopic Radical Prostatectomy 29Pardeep Kumar and Declan Cahill 10 Robotic Radical Prostatectomy 33Ben Challacombe and Jim Peabody 11 Prostate Brachytherapy 37Peter Acher and Rick Popert 12 HIFU 40Louise Dickinson Hashim U. Ahmed and Mark Emberton 13 Cryotherapy for Prostate Cancer 44Alastair Henderson and John Davies 14 Advances in External Beam Radiotherapy 48David Landau Nadia Walsh and Asad Qureshi 15 Recent Advances in Hormonal Therapy 51Heather Payne Reena Davda and Mark R. Feneley 16 Management of Castration-Resistant Prostate Cancer 54Roger S. Kirby Prokar Dasgupta and John M. Fitzpatrick 17 Immunology of Prostate Cancer 57Oussama Elhage Christine Galustian Richard Smith and Prokar Dasgupta 18 New Approaches to Prostate Cancer 63Megan S. Schober Roger S. Kirby and Prokar Dasgupta Index 67

    10 in stock

    £30.95

  • Elsevier Health Sciences Nathan and Oskis Hematology and Oncology of

    Out of stock

    Book SynopsisTrade Review"This is a comprehensive, accurate, and up-to-date publication on the major issues in pediatric hematology/oncology. Both the book and the website are outstanding resources for any of the intended users -- students, practitioners, clinical and research investigators." ~Joseph Rosenthal, MD, City of Hope Doody Score: 4 stars "This is an extremely useful, indispensable print and online resource on diseases of infants and children relating to the blood and cancer. It is a massive reference source that is well-researched, expertly organized and thoughtfully written." ~Nano KhilnaniTable of ContentsSection I Neonatal Hematology 1. Anatomy and Physiology of Hematopoiesis 2. The Neonatal Erythrocyte and Its Disorders 3. Immune Hemolytic Disease 4. Neonatal Jaundice and Disorders of Bilirubin Metabolism 5. Hemostasis in the Newborn and Infant Section II Bone Marrow Failure 6. Acquired Aplastic Anemia and Pure Red Cell Aplasia 7. Inherited Bone Marrow Failure Syndromes 8. Principles of Bone Marrow and Stem Cell Transplantation Section III Disorders of Erythrocyte Production 9. Diagnostic Approach to the Anemic Patient 10. Megaloblastic Anemia 11. Disorders of Iron and Copper Metabolism, Sideroblastic Anemias and Lead Toxicity 12. Porphyrias Section IV Hemolytic Anemias 13. Autoimmune Hemolytic Anemia 14. Paroxysmal Nocturnal Hemoglobinuria 15. Red Cell Membrane 16. Disorders of the Red Cell Membrane 17. Pyruvate Kinase Deficiency and Disorders of Glycolysis 18. Glucose-6-Phosphate Dehydrogenase Deficiency 19. Normal and Abnormal Hemoglobins Section V Disorders of Hemoglobin 20. Sickle Cell Disease 21. Thalassemias Section VI Phagocyte System 22. Phagocyte System and Disorders of Granulopoiesis and Granulocyte Function Section VII Immune System 23. Immune Response 24. Primary Immunodeficiency Diseases Section VIII Storage Diseases 25. Lysosomal Storage Diseases Section IX Hemostasis 26. Platelets and the Vessel Wall 27. Blood Coagulation 28. Molecular Basis of Fibrinolysis 29. Approach to the Child with a Suspected Bleeding Disorder 30. Inherited Platelet Disorders 31. Hemophilia and von Willebrand Disease 32. Rare Hereditary Coagulation Factor Abnormalities 33. Inherited Disorders of Thrombosis and Fibrinolysis 34. Acquired Platelet Defects 35. Acquired Disorders of Hemostasis Section X Supportive Therapy 36. Transfusion Medicine Section XI Hematologic Manifestations of Systemic Diseases 37. Hematological Manifestations of Systemic Diseases 38. Hematology Manifestations of Systemic Diseases in Children of the Developing World Section XII Biology of Cancer 39. Origins and Evolution of Pediatric Cancer 40. Epidemiology of Leukemia in Childhood 41. Informatics 42. Genetic Predisposition to Cancer 43. Genetic and Epigenetics of Childhood Cancers 44. Targeted Therapies in Oncology 45. Cytogenetic and Molecular Pathology of Pediatric Cancer Section XIII Pediatric Cancer Therapeutics 46. Cancer Chemotherapy for Pediatric Patients 47. Immunotherapy of Cancer 48. Pediatric Radiation Oncology 48. Pediatric Surgical Oncology Section XIV Hematologic Malignancy 50. Acute Lymphoblastic Leukemia 51. Pediatric Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease 52. Infant Leukemias 53. Pediatric Lymphoma Section XV Solid Tumors 54. Neuroblastoma 55. Pediatric Renal Tumors 56. Retinoblastoma 57. Tumors of the Brain and Spinal Cord 58. Hepatoblastoma and Other Liver Tumors in Children 59. Rhabdomyosarcoma 60. Nonrhabdomyosarcoma Soft Tissue Sarcomas and Other Soft Tissue Tumors 61. Ewing Sarcoma 62. Osteosarcoma 63. Pediatric Germ Cell Tumors 64. Histiocytoses 65. Rare Tumors of Childhood 66. Imaging in the Evaluation and Management of Childhood Cancer Section XVI Supportive Care 67. Infectious Disease in the Pediatric Cancer Patient 68. Oncologic Emergencies 69. Nursing Care of Patients with Childhood Cancer 70. Palliative Care in Pediatric Oncology 71. Symptom Management in Children with Cancer 72. Childhood Cancer Survivorship 73. Psychosocial Care of the Child and Family 74. Ethical Considerations in Pediatric Oncology Clinical Trials Appendices: Reference Values in Infancy and Childhood

    Out of stock

    £276.29

  • AJCC Cancer Staging Atlas

    Springer AJCC Cancer Staging Atlas

    Out of stock

    Book Synopsis-Purposes and Principles of Cancer Staging.- Cancer Survival Analysis.- Lip and Oral Cavity.- Pharynx.- Larynx.- Nasal Cavity and Paranasal Sinuses.- Major Salivary Glands (Parotid, Submandibular, and Sublingual).- Thyroid.- Mucosal Melanoma of the Head and Neck.- Esophagus and Esophagogastric Junction.- Stomach.- Small Intestine.- Appendix.- Colon and Rectum.- Anus.- Gastrointestinal Stromal Tumor.- Neuroendocrine Tumors.- Liver.- Intrahepatic Bile Ducts.- Gallbladder.- Perihilar Bile Ducts.- Distal Bile Duct.- Ampulla of Vater.- Exocrine and Endocrine Pancreas.- Lung.- Pleural Mesothelioma.- Bone.- Soft Tissue Sarcoma.- Cutaneous Squamous Cell Carcinoma and Other Cutaneous Carcinomas.- Merkel Cell Carcinoma.- Melanoma of the Skin.- Breast.- Vulva.- Vagina.- Cervix Uteri.- Corpus Uteri.- Ovary and Primary Peritoneal Carcinoma.- Fallopian Tube.- Gestational Trophoblastic Tumors.- Penis.- Prostate.- Testis.- Kidney.- Renal Pelvis and Ureter.- Urinary Bladder.- Urethra.- Adrenal.- Hod

    Out of stock

    £999.99

  • CancerCausing Viruses and Their Inhibitors

    Taylor & Francis Inc CancerCausing Viruses and Their Inhibitors

    Out of stock

    Book SynopsisCancer-causing viruses, also called oncoviruses, play a key role in the development of certain cancers. They contribute to genetic changes that disrupt the cell cycle machinery, interfering with functions such as cell growth. Cancer-Causing Viruses and Their Inhibitors presents a plethora of research from internationally reputed contributors who discuss different types of oncoviruses, their mechanisms of invasion and growth, and their life cycles. The book begins with an overview of the oncoviruses discovered to date and includes a brief description of their structures, genotypes, replication, and mechanisms of infection leading to cancers. It then explores several of these viruses in detail, including: Human T-cell leukemia virus type 1 (HTLV-1) Hepatitis C virus (HCV) EpsteinBarr virus (EBV) Human papilloma virus (HPV) Human herpes virus 8 (HHV-8)/Kaposi's sarcoma-associatTable of Contents Cancer Causing Viruses: An Introduction. Targeting Human T-Cell Leukemia Virus Type 1: Pathogenesis and Treatment Strategies. Hepatitis C Virus and Its Inhibitors: The Polymerase as a Target for Nucleoside and Nucleotide Analogs. Mechanisms of Hepatitis C Virus Clearance by Interferon and Ribavirin Combination: Lessons Learned from In Vitro Cell Culture. Hepatitis B Virus Infection and Hepatocellular Carcinoma. Epstein–Barr Virus and Treatment of Its Infection. Landscape of Papilloma Virus in Human Cancers: Prevention and Therapeutic Avenues. Role of High-Risk Human Papillomaviruses in Breast Carcinogenesis. Prospective Therapies of Genital Human Papillomavirus Infections. Human Herpesvirus Type 8/Kaposi Sarcoma Herpesvirus: An Overview of Viral Pathogenesis and Treatment of Associated Diseases. Tea Polyphenolic Compounds against Herpes Simplex Viruses. HIV Integrase Inhibitors: Qualitative and Quantitative Structure-Activity Relationship Studies. Virus Wars: Oncolytic versus Oncogenic Viruses. Oncolytic Viruses and Histone Deacetylase Inhibitors. Index.

    Out of stock

    £999.99

  • Communicating with Cancer Patients

    Taylor & Francis Inc Communicating with Cancer Patients

    1 in stock

    Book SynopsisPublished in association with the European Society of Medical Oncology, this book is designed for trainee oncologists, oncology nurses, and those working with cancer patients on a day-to-day basis. Using an accessible writing style suitable for a wide audience of caregivers, the book focuses on the soft skills required in communicating with patients. Topics include the aetiology of cancer, diagnosis and staging, and explaining the purpose of treatment, including chemotherapy, hormone treatment, and immunological and gene-based therapies. The book also discusses patient support groups, monitoring remission, and relapse. Communicating with Cancer Patients is written by UK oncologists but has wide international application.Trade Review"… a super little book. On the whole this is a well written and easy to read text. one that I would recommend … "—Dr Karin Baria, Retired Consuftam Oncologist, Oncology News, Volume 10 Issue 1 - March/ApriI 20 15Table of ContentsIntroduction. The different phases of management. The aetiology of cancer. Diagnosis and Staging. Environment. Referral letter. Results and investigations to date. Observation. History. Examination. Performance status. Investigations. Next steps. Questions. Primary Treatment. Cytotoxic chemotherapy. Hormone treatment. Immunological therapy. Gene-based therapies. Explaining the purpose of treatment. Communication within the Context of Multidisciplinary Care. Oncology nurses. Psychosocial oncologists. Patient support groups and the internet. Explaining Follow-up. Monitoring remission. Relapse. Progression and Terminal Care. Explaining Research. Complementary and Alternative Medicines and Integrative Oncology.

    1 in stock

    £27.99

  • Intraperitoneal Cancer Therapy

    Taylor & Francis Inc Intraperitoneal Cancer Therapy

    1 in stock

    Book SynopsisIntraperitoneal Cancer Therapy: Principles and Practice is one of the first books to combine the latest clinical developments in the treatment of patients with peritoneal surface disease and the scientific principles that underlie the concept of intraperitoneal cancer therapy. The book covers basic concepts such as anatomy, physiology, pharmacology, and mathematical models of drug transport as well as practical clinical applications, highlighted with results from clinical trials and promising novel preclinical developments.The book is a state-of-the-art reference for surgical and medical oncologists interested in the treatment of carcinomatosis. It also establishes and promotes basic and translational research interest in the field of intraperitoneal drug delivery, which has the potential to improve the outcome for this dreaded condition. Edited by two renowned surgical oncologists, it represents the definitive reference in the field of intraperitonealTrade Review"The unique feature of this book is its complete coverage of all essentials for treating peritoneal surface malignancies -- it is truly a "one stop shop"… The quality of this book is superb and the digital version provides an extra dimension. It is unique in the comprehensive coverage of this highly specific topic and cannot readily be compared to other books." - Carlos HF Chan, MD, PhD (University of Iowa Hospitals and Clinics), 5 stars, Doody Enterprises"The unique feature of this book is its complete coverage of all essentials for treating peritoneal surface malignancies -- it is truly a "one stop shop"… The quality of this book is superb and the digital version provides an extra dimension. It is unique in the comprehensive coverage of this highly specific topic and cannot readily be compared to other books." —5 stars (100/100), Carlos HF Chan, MD, PhD (University of Iowa Hospitals and Clinics), Doody's Book Review ServiceTable of ContentsPERITONEUM: EMBRYOLOGY, ANATOMY, AND PHYSIOLOGY. Embryology and Anatomy of the Peritoneal Cavity. Structure and Function of the Mesothelial Cell. Applied Radiological Anatomy of the Peritoneal Cavity. Peritoneal Drug Transport. PERITONEAL CARCINOMATOSIS: BASIC MECHANISMS. Molecular Biology of Peritoneal Carcinomatosis. Dissemination and Adhesion of Peritoneal Cancer Cells to the Peritoneal Wall. Genomic Approaches to Peritoneal Carcinomatosis. Surgery, Wound Healing, and Peritoneal Minimal Residual Disease in Colorectal Cancer. Role of the Greater Omentum in the Pathogenesis of Peritoneal Carcinomatosis. Lymphatic Transport and the Diaphragmatic Stomata. INTRAPERITONEAL DRUG THERAPY: BASIC PRINCIPLES. Pharmacokinetics of Intraperitoneal Cytotoxic Drug Therapy. Tissue Transport and Pharmacodynamics of Intraperitoneal Chemotherapy. Mathematical Models of Intraperitoneal Drug Delivery. SURGICAL TECHNIQUES FOR INTRAPERITONEAL DRUG DELIVERY. Management of Peritoneal Metastases Using Cytoreductive Surgery and Perioperative Chemotherapy. Chemoperfusion Techniques and Technologies. Port Placement for Intraperitoneal Chemotherapy. CLINICAL RESULTS OF INTRAPERITONEAL DRUG DELIVERY. Intraperitoneal Chemotherapy for Ovarian Cancer. Cytoreductive Surgery and HIPEC in the Treatment of Advanced Epithelial Ovarian Cancer and Serous Papillary Peritoneal Carcinoma. Pseudomyxoma Peritonei. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer with Peritoneal Surface Disease. Diffuse Malignant Peritoneal Mesothelioma: Current Concepts in Evaluation and Management. Gastric Cancer and Intraperitoneal Chemotherapy. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Small Bowel Adenocarcinoma. Peritoneal Surface Malignancy from Neuroendocrine Tumors. Treatment Considerations for High-Grade Appendiceal Adenocarcinoma. Systemic Therapy for Appendiceal Cancer. Toxicity and Morbidity of IP Drug Therapy. Safety Considerations and Occupational Hazards. Role of CRS/HIPEC in the Management of Malignant Ascites. NOVEL AND EXPERIMENTAL APPROACHES. Development of Drug-Loaded Particles for Intraperitoneal Therapy. Biomaterials and Drug Delivery Systems for Intraperitoneal Chemotherapy. Intraperitoneal Nonviral Nucleic Acid Delivery in the Treatment of Peritoneal Cancer. Immunotherapy of Peritoneal Carcinomatosis. The Promise of Oncolytic Viral Therapy for the Treatment of Peritoneal Surface Malignancies. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).

    1 in stock

    £190.00

© 2026 Book Curl

    • American Express
    • Apple Pay
    • Diners Club
    • Discover
    • Google Pay
    • Maestro
    • Mastercard
    • PayPal
    • Shop Pay
    • Union Pay
    • Visa

    Login

    Forgot your password?

    Don't have an account yet?
    Create account